<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Rare Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4403</journal-id><journal-id journal-id-type="pmc-domain">tard</journal-id><journal-id journal-id-type="publisher-id">TRD</journal-id><journal-title-group><journal-title>Therapeutic Advances in Rare Disease</journal-title></journal-title-group><issn pub-type="epub">2633-0040</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10032470</article-id><article-id pub-id-type="pmcid-ver">PMC10032470.1</article-id><article-id pub-id-type="pmcaid">10032470</article-id><article-id pub-id-type="pmcaiid">10032470</article-id><article-id pub-id-type="pmid">37180424</article-id><article-id pub-id-type="doi">10.1177/26330040211070295</article-id><article-id pub-id-type="publisher-id">10.1177_26330040211070295</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Therapeutic angiogenesis in Buerger&#8217;s disease: reviewing the
treatment landscape</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7380-3435</contrib-id><name name-style="western"><surname>Ribieras</surname><given-names initials="AJ">Antoine J.</given-names></name><aff id="aff1-26330040211070295">DeWitt Daughtry Family Department of Surgery,
University of Miami Miller School of Medicine, Miami, FL, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ortiz</surname><given-names initials="YY">Yulexi Y.</given-names></name><aff id="aff2-26330040211070295">DeWitt Daughtry Family Department of Surgery,
University of Miami Miller School of Medicine, Miami, FL, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="ZJ">Zhao-Jun</given-names></name><aff id="aff3-26330040211070295">DeWitt Daughtry Family Department of Surgery,
University of Miami Miller School of Medicine, RMSB 1046, 1600 NW 10th
Avenue, Miami, FL 33136, USA. Vascular Biology Institute, University of
Miami Miller School of Medicine, Miami, FL, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Velazquez</surname><given-names initials="OC">Omaida C.</given-names></name><xref rid="corresp2-26330040211070295" ref-type="corresp"/><aff id="aff4-26330040211070295">DeWitt Daughtry Family Department of Surgery,
University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami,
FL 33136, USA. Vascular Biology Institute, University of Miami Miller School
of Medicine, Miami, FL, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review &amp; editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-26330040211070295"><email>zliu@med.miami.edu</email></corresp><corresp id="corresp2-26330040211070295"><email>ovelazquez@med.miami.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2022</year></pub-date><volume>3</volume><issue-id pub-id-type="pmc-issue-id">431834</issue-id><elocation-id>26330040211070295</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>7</day><month>12</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>11</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-14 02:25:17.403"><day>14</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_26330040211070295.pdf"/><abstract><p>Thromboangiitis obliterans, also known as Buerger&#8217;s disease, is a rare
inflammatory vasculitis that predominantly develops in smokers and
characteristically affects the small- and medium-sized peripheral arteries and
veins. Patients typically present with extremity claudication, but symptoms may
progress to rest pain and tissue loss, especially in those unable to abstain
from tobacco use. Unfortunately, traditional medical treatments are largely
ineffective and due to the small caliber of affected vessels and lack of
suitable distal targets or venous conduits, endovascular and open surgical
approaches are often not possible. Eventually, a significant number of patients
require major amputation. For these reasons, much research effort has been made
in developing techniques of therapeutic angiogenesis to improve limb perfusion,
both for atherosclerotic peripheral arterial disease and the smaller subset of
patients with critical limb ischemia due to Buerger&#8217;s disease.
Neovascularization in response to ischemia relies on a complex interplay between
the local tissue microenvironment and circulating stem and progenitor cells. To
date, studies of therapeutic angiogenesis have therefore focused on exploiting
known angiogenic factors and stem cells to induce neovascularization in ischemic
tissues. This review summarizes the available clinical data regarding the safety
and efficacy of various angiogenic therapies, notably injection of naked DNA
plasmids, viral gene constructs, and cell-based preparations, and describes
techniques for potentiating <italic toggle="yes">in vivo</italic> efficacy of gene- and
cell-based therapies as well as ongoing developments in exosome-based cell-free
approaches for therapeutic angiogenesis.</p><sec id="section1-26330040211070295"><title>Plain Language Title and Summary</title><p>
<italic toggle="yes">A review of available and emerging treatments for improving blood
flow and wound healing in patients with Buerger&#8217;s disease, a rare
disorder of blood vessels</italic>
</p><p>Buerger&#8217;s disease is a rare disorder of the small- and medium-sized blood
vessels in the arms and legs that almost exclusively develops in young
smokers. Buerger&#8217;s disease causes inflammation in arteries and veins, which
leads to blockage of these vessels and reduces blood flow to and from the
extremities. Decreased blood flow to the arms and legs can lead to
development of nonhealing wounds and infection for which some patients may
eventually require amputation. Unfortunately, traditional medical and
surgical treatments are not effective in Buerger&#8217;s disease, so other methods
for improving blood flow are needed for these patients. There are several
different ways to stimulate new blood vessel formation, both in humans and
animal models. The most common treatments involve injection of DNA or
viruses that express genes related to blood vessel formation or,
alternatively, stem cell&#8211;based treatments that help regenerate blood vessels
and repair wound tissue. This review explores how safe and effective these
various treatments are and describes recent research developments that may
lead to better therapies for patients with Buerger&#8217;s disease and other
vascular disorders.</p></sec></abstract><kwd-group><kwd>Buerger&#8217;s disease</kwd><kwd>critical limb ischemia</kwd><kwd>gene therapy</kwd><kwd>neovascularization</kwd><kwd>therapeutic angiogenesis</kwd><kwd>thromboangiitis obliterans</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2022</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section2-26330040211070295"><title>Background</title><sec id="section3-26330040211070295"><title>Epidemiology</title><p>Thromboangiitis obliterans (TAO) is a rare inflammatory vasculitis that affects
the small- and medium-sized arteries and veins of the arms and legs. The disease
was first described by Felix Von Winiwarter in 1879 but later named after Leo
Buerger who, in 1908, provided a detailed pathological account in 11 amputated
limbs.<sup><xref rid="bibr1-26330040211070295" ref-type="bibr">1</xref></sup> Buerger&#8217;s disease predominantly develops in young to
middle-aged male tobacco users,<sup><xref rid="bibr2-26330040211070295" ref-type="bibr">2</xref>,<xref rid="bibr3-26330040211070295" ref-type="bibr">3</xref></sup> and most investigators
agree that exposure to tobacco, whether firsthand or secondhand, is a
prerequisite for development of the disease.<sup><xref rid="bibr4-26330040211070295" ref-type="bibr">4</xref></sup> In a recent Japanese study,
however, up to 8% of patients identified as never smokers. Never smoker patients
tended to present with milder symptoms, but as objective nicotine testing was
not performed, this population may represent patients with an unrecognized
milder secondhand exposure to tobacco.<sup><xref rid="bibr5-26330040211070295" ref-type="bibr">5</xref></sup> In the United States,
incidence of Buerger&#8217;s disease has been declining alongside smoking rates and is
now estimated as 12.6&#8211;20 per 100,000 people.<sup><xref rid="bibr6-26330040211070295" ref-type="bibr">6</xref></sup> In parts of Asia and the
Far and Middle East, however, the disease is much more prevalent.<sup><xref rid="bibr6-26330040211070295" ref-type="bibr">6</xref></sup> In India,
for example, between 45% and 63% of patients with peripheral arterial disease
(PAD) are suspected of having Buerger&#8217;s disease, while in Korea and Japan,
Buerger&#8217;s disease represents 16&#8211;66% of PAD cases.<sup><xref rid="bibr2-26330040211070295" ref-type="bibr">2</xref>,<xref rid="bibr4-26330040211070295" ref-type="bibr">4</xref>,<xref rid="bibr6-26330040211070295" ref-type="bibr">6</xref></sup></p></sec><sec id="section4-26330040211070295"><title>Clinical features</title><p>Buerger&#8217;s disease presents with ischemic symptoms of the distal upper and, more
commonly, lower extremities. While the disease can progress proximally,
involvement of large arteries is rare, especially in the absence of small vessel
disease.<sup><xref rid="bibr6-26330040211070295" ref-type="bibr">6</xref></sup> Typical symptoms are claudication of the hands, arms,
feet, or legs, with severe disease leading to rest pain and ulceration. More
than one limb is often affected. In a series of 112 patients with Buerger&#8217;s
disease, 85 of whom had ischemic ulcerations, 28% had upper extremity, 46% lower
extremity, and 26% both upper and lower extremity lesions.<sup><xref rid="bibr7-26330040211070295" ref-type="bibr">7</xref></sup></p><p>Patients with ischemic ulcerations are at risk of developing chronic nonhealing
wounds with superimposed infection that may ultimately require amputation.
Compared with patients with critical limb ischemia (CLI) due to atherosclerotic
PAD, patients with Buerger&#8217;s disease tend to present at younger age and with
fewer comorbidities. As such, overall survival remains favorable. However,
vascular events are common and represent a significant source of morbidity for
this population. In a 2018 study of 224 patients with Buerger&#8217;s disease treated
in France between 1970 and 2016, 5-, 10-, and 15-year vascular event-free
survival was 41%, 23%, and 19% and amputation-free survival was 85%, 74%, and
66%.<sup><xref rid="bibr8-26330040211070295" ref-type="bibr">8</xref></sup> Limb infection and nonwhite race conferred additional risk
for vascular complications, and conversely, patients who quit using tobacco had
lower risk of amputation that those who continued.</p></sec><sec id="section5-26330040211070295"><title>Pathophysiology</title><p>In contrast to atherosclerotic PAD, endarteritis in Buerger&#8217;s disease is
nonatherosclerotic by definition and can affect both arteries and veins.
Pathologically, Buerger&#8217;s disease progresses in three distinct phases. In the
acute phase, the most diagnostic, a hypercellular inflammatory infiltrate
accumulates within the vessel lumen. Vascular inflammation fosters a local
prothrombotic state which leads to vaso-occlusion and then microabscess
formation. Subacutely, granulomatous inflammation develops, and the thrombus is
reorganized and recanalized. As the thrombus matures chronically, vascular
fibrosis ensues, leaving a stenotic arterial lumen that clinically mimics
lesions of atherosclerosis (<xref rid="fig1-26330040211070295" ref-type="fig">Figure 1</xref>).<sup><xref rid="bibr2-26330040211070295" ref-type="bibr">2</xref></sup></p><fig position="float" id="fig1-26330040211070295" orientation="portrait"><label>Figure 1.</label><caption><p>Pathogenesis of atherosclerotic PAD and Buerger&#8217;s disease. Prolonged
exposure to atherosclerotic risk factors leads to plaque formation and
arterial stenoses in atherosclerotic PAD. In Buerger&#8217;s disease, tobacco
smoking triggers an inflammatory response in susceptible individuals
leading to progressive thrombosis and fibrosis of small and medium-sized
vessels. Both disease processes lead to luminal stenosis and
location-dependent symptoms of tissue ischemia. Despite
revascularization attempts, many patients with chronic nonhealing wounds
develop gangrenous changes and superimposed infection which necessitate
amputation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_26330040211070295-fig1.jpg"/></fig><p>While tobacco exposure is central to disease onset and continuation, the precise
mechanisms of disease initiation remain unknown. Genetic predisposition
certainly plays a role as several polymerase chain reaction (PCR)-based studies
have identified specific human leukocyte antigen (HLA) class I and II alleles
associated with increased odds of developing Buerger&#8217;s disease.<sup><xref rid="bibr9-26330040211070295" ref-type="bibr">9</xref>
<xref rid="bibr10-26330040211070295" ref-type="bibr"/>&#8211;<xref rid="bibr11-26330040211070295" ref-type="bibr">11</xref></sup> In susceptible
individuals, exposure to tobacco may incite an aberrant immune reaction toward
endothelium via toll-like receptor (TLR) signaling and the TLR-MyD88-NF&#954;B
pathway.<sup><xref rid="bibr12-26330040211070295" ref-type="bibr">12</xref></sup> Serologic analyses have also found increased levels of
circulating pro-inflammatory (IL-1&#946;, TNF-&#945;, and IL-6), type 1 helper cell (IFN-&#947;
and IL-12), and type 2 helper cell cytokine profiles (IL-4, IL-5, and IL-13) in
patients with Buerger&#8217;s disease, as well as those of type 17 helper cells (IL-17
and IL-23) which are strongly associated with autoimmunity.<sup><xref rid="bibr13-26330040211070295" ref-type="bibr">13</xref></sup></p></sec><sec id="section6-26330040211070295"><title>Diagnosis</title><p>Careful history-taking and physical examination are critical for identifying
Buerger&#8217;s disease. Diagnostic criteria by Shionoya<sup><xref rid="bibr14-26330040211070295" ref-type="bibr">14</xref></sup> and Olin<sup><xref rid="bibr4-26330040211070295" ref-type="bibr">4</xref></sup> and a
scoring system by Papa <italic toggle="yes">et al.</italic><sup><xref rid="bibr15-26330040211070295" ref-type="bibr">15</xref></sup> all utilize common
elements including history of tobacco use, onset before the age of 45&#8211;50 years,
documentation of peripheral vascular disease by noninvasive or angiographic
imaging, and exclusion of other etiologies, such as atherosclerosis, proximal
embolic source, hypercoagulable state, diabetes, and autoimmune
disorders.<sup><xref rid="bibr4-26330040211070295" ref-type="bibr">4</xref>,<xref rid="bibr14-26330040211070295" ref-type="bibr">14</xref>
<xref rid="bibr15-26330040211070295" ref-type="bibr"/><xref rid="bibr16-26330040211070295" ref-type="bibr"/>&#8211;<xref rid="bibr17-26330040211070295" ref-type="bibr">17</xref></sup> Workup for Buerger&#8217;s
disease should focus on ruling out other disease processes with similar
presenting signs and symptoms. Routine laboratory tests, including complete
blood count with differential, renal and liver function tests, erythrocyte
sedimentation rate, and C-reactive protein levels are indicated, as well as
markers of certain autoimmune conditions, notably rheumatoid factor (rheumatoid
arthritis and vasculitis), antinuclear antibody (systemic lupus erythematosus,
SLE), anticentromere antibody (CREST syndrome: calcinosis, Raynaud&#8217;s phenomenon,
esophageal dysmotility, sclerodactyly, telangiectasia), and serum
antitopoisomerase (scleroderma). Hypercoagulability screening is also indicated
given the pathogenic role of thrombosis in this disease.</p><p>Angiographic evaluation can provide both diagnostic information and, in select
cases, opportunity for therapeutic intervention. Characteristic angiographic
findings include segmental stenoses or occlusions of the small- and medium-sized
arteries distal to the brachial and popliteal arteries in the arms and legs,
respectively. As such, the vessels most commonly involved are the palmar,
radial, ulnar, and digital arteries in the upper extremities and the plantar,
tibial, and peroneal arteries in the lower extremities. Corkscrew collaterals,
known as Martorell&#8217;s sign, can reflect compensatory changes in the vasa vasorum,
although similar changes may be observed in other autoimmune vasculitides and
connective tissue disorders.<sup><xref rid="bibr4-26330040211070295" ref-type="bibr">4</xref>,<xref rid="bibr18-26330040211070295" ref-type="bibr">18</xref></sup></p></sec><sec id="section7-26330040211070295"><title>Burden of disease</title><p>Failure of medical and surgical treatment in Buerger&#8217;s disease is multifactorial.
Smoking cessation remains the mainstay of treatment, and those unable to do so
are at increased risk of persistent disease and complications from surgical
interventions. In addition, some patients present with late-stage, irreversible
features such as digital gangrene which cannot be ameliorated by limb
reperfusion. Given the autoimmune nature of this disease, individual variations
in genetic and environmental background may also predispose certain patients to
recurrent disease. In some cases, tissue loss may be severe enough to require
amputation of the affected digit or limb. The risk of any amputation has been
reported as 25% at 5 years, 38% at 10 years, and 46% at 20 years, and that of
major amputation (above-the-knee, below-the-knee, or hand amputation) as 11% at
5 years, 21% at 10 years, and 23% at 20 years.<sup><xref rid="bibr19-26330040211070295" ref-type="bibr">19</xref></sup> Patients undergoing
amputation for gangrene or infection often face impaired mobility, reduced
quality of life and psychosocial well-being, and increased healthcare costs. One
study reported that 85% of patients with Buerger&#8217;s disease who underwent major
lower limb amputation lost their jobs compared with 9% of those who did not
require amputation.<sup><xref rid="bibr20-26330040211070295" ref-type="bibr">20</xref></sup> Compared with a matched US population, patients with
Buerger&#8217;s disease also had worse overall survival with average lifespan of 52.2
years. These findings highlight that despite earlier age and fewer comorbidities
at presentation compared with patients with atherosclerotic PAD, patients with
Buerger&#8217;s disease still face significant disease-related morbidity.</p></sec><sec id="section8-26330040211070295"><title>Current medical therapy</title><p>Cessation of all tobacco use remains the most important intervention in Buerger&#8217;s
disease but substituting for smokeless tobacco does not appear to prevent limb
loss.<sup><xref rid="bibr21-26330040211070295" ref-type="bibr">21</xref></sup> Various pharmacological treatments have been used in the
care of patients with Buerger&#8217;s disease, including anticoagulants,
thrombolytics, vasodilators, and anti-inflammatory drugs; however, most of these
therapies are ineffective. A recent <italic toggle="yes">Cochrane</italic> meta-analysis of
five randomized controlled trials (RCTs) with a total of 602 patients evaluated
the efficacy of several intravenous and oral therapies in treating Buerger&#8217;s
disease.<sup><xref rid="bibr22-26330040211070295" ref-type="bibr">22</xref></sup> Compared with aspirin, intravenous iloprost, a
prostacyclin (PGI2) analogue, was effective in healing ulcers and eradicating
rest pain after 28 days of treatment but had no effect on amputation rate 6
months after treatment.<sup><xref rid="bibr22-26330040211070295" ref-type="bibr">22</xref>,<xref rid="bibr23-26330040211070295" ref-type="bibr">23</xref></sup> In addition, there was no difference in ulcer healing
rate between prostacyclin (iloprost and clinprost) and prostaglandin
(alprostadil) analogues, and oral iloprost was no more effective than placebo
for healing of ischemic ulcers and resolution of rest pain.<sup><xref rid="bibr22-26330040211070295" ref-type="bibr">22</xref>,<xref rid="bibr24-26330040211070295" ref-type="bibr">24</xref></sup> Outcomes
data from these studies remain limited as none of the trials evaluated
amputation-free survival, pain-free walking distance, or ankle-brachial indices
(ABI).</p></sec><sec id="section9-26330040211070295"><title>Current surgical therapy</title><p>Surgical treatment of Buerger&#8217;s disease is limited by the small caliber of
peripheral vessels typically involved. While angiography may be performed for
diagnostic purposes, the affected arteries are often too small to access for
angioplasty. In recent series, however, outcomes following percutaneous
transluminal angioplasty (PTA) have been more favorable with technical success
and limb salvage rates as high as 92&#8211;96% and 92&#8211;100%, respectively.<sup><xref rid="bibr25-26330040211070295" ref-type="bibr">25</xref>
<xref rid="bibr26-26330040211070295" ref-type="bibr"/><xref rid="bibr27-26330040211070295" ref-type="bibr"/>&#8211;<xref rid="bibr28-26330040211070295" ref-type="bibr">28</xref></sup> Although reintervention
is required in approximately 30% of endovascular cases,<sup><xref rid="bibr25-26330040211070295" ref-type="bibr">25</xref></sup> outcomes
following open vascular reconstruction are significantly worse, partially due to
lack of suitable venous conduits. In a retrospective study of 110 patients with
Buerger&#8217;s disease, primary graft patency was 41% at 1 year, 32% at 5 years, and
30% at 10 years for 46 bypasses performed.<sup><xref rid="bibr20-26330040211070295" ref-type="bibr">20</xref></sup> Secondary graft patency
was 54% at 1 year, 47% at 5 years, and 39% at 10 years. All bypasses with
prosthetic, bovine, or composite grafts were occluded within 10 months and, in
patients with failed grafts, amputation was required in 5 of 35 limbs (14%). In
inoperable cases, lumbar sympathectomy is sometimes offered to help reduce pain
and increase perfusion via vasodilatory effect. However, the only RCT evaluating
sympathectomy in Buerger&#8217;s disease found inferior benefit for pain relief and
wound healing compared with intravenous iloprost.<sup><xref rid="bibr29-26330040211070295" ref-type="bibr">29</xref></sup></p></sec></sec><sec id="section10-26330040211070295"><title>Therapeutic angiogenesis</title><p>Other than smoking cessation, standard medical and surgical therapies for Buerger&#8217;s
disease remain limited. In parallel, as many as 25&#8211;40% of patients with CLI due to
atherosclerotic PAD are no longer eligible for or have failed prior
revascularization attempts.<sup><xref rid="bibr30-26330040211070295" ref-type="bibr">30</xref></sup> As such, both for Buerger&#8217;s disease and no-option CLI
patients, alternative methods of improving limb perfusion are needed. With this goal
in mind, significant research efforts have been made in developing gene and
cell-based therapies to promote neovascularization in ischemic tissues, otherwise
referred to as therapeutic angiogenesis. The term neovascularization encompasses all
types of new blood vessel formation. In response to tissue hypoxia, endothelial
cells (ECs) may be stimulated to sprout capillaries from pre-existing vessels
(angiogenesis) or recruited from a pool of circulating stem and progenitor cells
(vasculogenesis) to areas in need of new blood vessels (<xref rid="fig2-26330040211070295" ref-type="fig">Figure 2</xref>).<sup><xref rid="bibr31-26330040211070295" ref-type="bibr">31</xref></sup> In contrast, arteriogenesis
refers to collateral formation in response to arterial occlusion and resulting shear
stress forces. Arteriogenesis therefore plays an important role in compensating for
large vessel occlusion seen in atherosclerotic PAD, but vascular remodeling
secondary to small vessel disease, such as that in Buerger&#8217;s disease, relies
primarily on angiogenesis and vasculogenesis.</p><fig position="float" id="fig2-26330040211070295" orientation="portrait"><label>Figure 2.</label><caption><p>Sequence of events in angiogenesis and points of action of various angiogenic
therapies. Tissue hypoxia, ischemia, and injury lead to the release of
pro-inflammatory cytokines from stromal cells. Activated endothelium
expresses a variety of CAMs via HIF-1 and other response pathways to recruit
EPCs necessary for vasculogenesis and MSCs that support the local tissue
microenvironment. Stromal cells secrete VEGF and other growth factors to
stimulate tip cell selection and migration, key steps in angiogenesis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_26330040211070295-fig2.jpg"/></fig><p>Stem and progenitor cells include endothelial progenitor cells (EPCs) that directly
contribute to blood vessel formation and mesenchymal stem cells (MSCs) that
influence the local stromal environment and support angiogenesis via paracrine
secretion of growth factors and cytokines/chemokines. In 1997, putative EPCs were
first characterized as CD34<sup>+</sup>/KDR<sup>+</sup> (CD34, marker of
stemness/immaturity; KDR, vascular endothelial growth factor receptor-2 (VEGFR2),
marker of endothelial commitment).<sup><xref rid="bibr32-26330040211070295" ref-type="bibr">32</xref></sup> EPCs arise from a heterogenic
pool of CD133<sup>+</sup> hemangioblasts that may differentiate into endothelial or
myeloid lineages.<sup><xref rid="bibr33-26330040211070295" ref-type="bibr">33</xref></sup> MSCs, however, are multipotent cells present in bone marrow,
adipose tissue, and the umbilical cord that may differentiate into various
connective tissue cells, including adipocytes, osteoblasts, myocytes, and
chondrocytes.</p><p>In Buerger&#8217;s disease, angiogenic potential is uniquely altered compared with
otherwise healthy smoker and nonsmoker patients. In a study comparing circulating
progenitor cells and angiogenic factor levels in these groups, both smokers and
patients with Buerger&#8217;s disease exhibited a decrease in the heterogenic pool of
circulating CD45<sup>+</sup>/CD34<sup>+</sup> progenitor cells. In Buerger&#8217;s disease
only, however, the number of endothelial-specific progenitor cells remained
comparable with healthy nonsmokers. Interestingly, despite similar levels of
angiogenic factors (vascular endothelial growth factor (VEGF), angiopoietin-1
(ANG-1), endoglin, endostatin, matrix metalloproteinase-8 (MMP-8)), only serum from
patients with Buerger&#8217;s disease impaired migration, sprouting, and proliferation of
human umbilical vein endothelial cells (HUVECs) <italic toggle="yes">in vitro</italic>.<sup><xref rid="bibr34-26330040211070295" ref-type="bibr">34</xref></sup> In contrast,
another study found reduced number of EPCs in patients with Buerger&#8217;s disease and
smokers, but no differences in endothelial cell function compared with healthy
nonsmokers.<sup><xref rid="bibr35-26330040211070295" ref-type="bibr">35</xref></sup> These contradictory findings highlight the poorly
understood relationship between tobacco use, endothelial cell function, and EPC
viability, but do suggest unique differences in angiogenic potential in patients
with Buerger&#8217;s disease compared with smoker and nonsmoker controls.</p></sec><sec id="section11-26330040211070295"><title>Gene therapies</title><p>In response to tissue hypoperfusion, angiogenic factors such as VEGF, ANG-1,
fibroblast growth factor (FGF), and various cytokines/chemokines are released by
inflammatory cells, thereby initiating a paracrine signaling cascade that leads to
pericyte detachment, endothelial permeabilization, and endothelial cell
migration.<sup><xref rid="bibr36-26330040211070295" ref-type="bibr">36</xref></sup> Given their pivotal role in angiogenesis, inducing
overexpression of such factors in ischemic tissue is a logical therapeutic approach.
To date, angiogenic factors have primarily been administered as naked DNA plasmids
encoding the respective gene of interest or DNA packaged with a viral gene delivery
vector. Given the higher prevalence of CLI due to atherosclerosis rather than
Buerger&#8217;s disease, many clinical trials of therapeutic angiogenesis have primarily
enrolled patients with atherosclerotic PAD. Nevertheless, results from these studies
are valuable and, in several cases, patients with Buerger&#8217;s disease are specifically
recruited in trials and included in analyses (<xref rid="table1-26330040211070295" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="table1-26330040211070295" orientation="portrait"><label>Table 1.</label><caption><p>Clinical trials of gene therapy in Buerger&#8217;s disease and atherosclerotic
PAD/CLI.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_26330040211070295-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Vector (delivery)</th><th align="left" rowspan="1" colspan="1">Population (<italic toggle="yes">N</italic>)</th><th align="left" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Baumgartner <italic toggle="yes">et al.</italic><sup><xref rid="bibr40-26330040211070295" ref-type="bibr">40</xref></sup></td><td rowspan="1" colspan="1">1998</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (9)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing, vascularity on DSA/MRA</td></tr><tr><td rowspan="1" colspan="1">Isner <italic toggle="yes">et al.</italic><sup><xref rid="bibr41-26330040211070295" ref-type="bibr">41</xref></sup></td><td rowspan="1" colspan="1">1998</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">BD (6)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing, vascularity on DSA/MRA</td></tr><tr><td rowspan="1" colspan="1">M&#228;kinen <italic toggle="yes">et al.</italic><sup><xref rid="bibr44-26330040211070295" ref-type="bibr">44</xref></sup></td><td rowspan="1" colspan="1">2002</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA and Adeno (IA)</td><td rowspan="1" colspan="1">PAD/CLI (17 plasmid, 18 Adeno, 19 placebo)</td><td rowspan="1" colspan="1">&#8593; Vascularity on DSA</td></tr><tr><td rowspan="1" colspan="1">Shyu <italic toggle="yes">et al.</italic><sup><xref rid="bibr42-26330040211070295" ref-type="bibr">42</xref></sup></td><td rowspan="1" colspan="1">2003</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (17)<break/>BD (4)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing, vascularity on DSA<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Kim <italic toggle="yes">et al.</italic><sup><xref rid="bibr43-26330040211070295" ref-type="bibr">43</xref></sup></td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">BD (7)<break/>ASO (2)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing, vascularity on DSA<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Kusumanto <italic toggle="yes">et al.</italic><sup><xref rid="bibr45-26330040211070295" ref-type="bibr">45</xref></sup></td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI and DM<break/>(27 plasmid, 27 placebo)</td><td rowspan="1" colspan="1">&#8593; Wound healing<break/>No change in amputation rate</td></tr><tr><td rowspan="1" colspan="1">Rajagopalan <italic toggle="yes">et al.</italic><sup><xref rid="bibr61-26330040211070295" ref-type="bibr">61</xref></sup></td><td rowspan="1" colspan="1">2003</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">VEGF</italic>
</td><td rowspan="1" colspan="1">Adeno (IM)</td><td rowspan="1" colspan="1">PAD/claudication (32 low dose, 40 high dose, 33 placebo)</td><td rowspan="1" colspan="1">No improvement in peak walking time, ABI, QOL</td></tr><tr><td rowspan="1" colspan="1">Morishita <italic toggle="yes">et al.</italic><sup><xref rid="bibr49-26330040211070295" ref-type="bibr">49</xref></sup></td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">BD (3)<break/>ASO (3)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Powell <italic toggle="yes">et al.</italic><sup><xref rid="bibr53-26330040211070295" ref-type="bibr">53</xref></sup></td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (26 low dose, 25 middle dose, 27 high dose, 26
placebo)</td><td rowspan="1" colspan="1">&#8593; TcPO<sub>2</sub> for high dose<break/>No difference in ABI,
wound healing, major amputation, or death</td></tr><tr><td rowspan="1" colspan="1">Powell <italic toggle="yes">et al.</italic><sup><xref rid="bibr54-26330040211070295" ref-type="bibr">54</xref></sup></td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (21 plasmid, 6 placebo)</td><td rowspan="1" colspan="1">&#8593; TBI<break/>&#8595; Rest pain<break/>No difference in amputation</td></tr><tr><td rowspan="1" colspan="1">Shigematsu <italic toggle="yes">et al.</italic><sup><xref rid="bibr55-26330040211070295" ref-type="bibr">55</xref></sup></td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (27 plasmid, 13 placebo)</td><td rowspan="1" colspan="1">&#8593; Combined endpoint of wound healing/rest pain<break/>No
difference in ABI</td></tr><tr><td rowspan="1" colspan="1">Morishita <italic toggle="yes">et al.</italic><sup><xref rid="bibr50-26330040211070295" ref-type="bibr">50</xref></sup></td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">ASO (14)<break/>BD (8)</td><td rowspan="1" colspan="1">Tolerated</td></tr><tr><td rowspan="1" colspan="1">Makino <italic toggle="yes">et al.</italic><sup><xref rid="bibr51-26330040211070295" ref-type="bibr">51</xref></sup></td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">ASO (14)<break/>BD (8)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Morishita <italic toggle="yes">et al.</italic><sup><xref rid="bibr52-26330040211070295" ref-type="bibr">52</xref></sup></td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">
<italic toggle="yes">HGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI and BD (27 plasmid, 6 placebo)</td><td rowspan="1" colspan="1">&#8593; Wound healing<break/>&#8595; Rest pain in DM</td></tr><tr><td rowspan="1" colspan="1">Comerota <italic toggle="yes">et al.</italic><sup><xref rid="bibr58-26330040211070295" ref-type="bibr">58</xref></sup></td><td rowspan="1" colspan="1">2002</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">
<italic toggle="yes">FGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (51 treated, 15 analyzed)</td><td rowspan="1" colspan="1">&#8593; ABI, TcPO<sub>2</sub>, wound healing<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Nikol <italic toggle="yes">et al.</italic><sup><xref rid="bibr59-26330040211070295" ref-type="bibr">59</xref></sup></td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">
<italic toggle="yes">FGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (59 plasmid, 66 placebo)</td><td rowspan="1" colspan="1">&#8595; Amputation rate<break/>No difference in wound healing</td></tr><tr><td rowspan="1" colspan="1">Belch <italic toggle="yes">et al.</italic><sup><xref rid="bibr60-26330040211070295" ref-type="bibr">60</xref></sup></td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">
<italic toggle="yes">FGF</italic>
</td><td rowspan="1" colspan="1">pDNA (IM)</td><td rowspan="1" colspan="1">PAD/CLI (259 plasmid, 266 placebo)</td><td rowspan="1" colspan="1">No difference in major amputation</td></tr><tr><td rowspan="1" colspan="1">Rajagopalan <italic toggle="yes">et al.</italic><sup><xref rid="bibr62-26330040211070295" ref-type="bibr">62</xref></sup></td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">
<italic toggle="yes">HIF-1&#945;</italic>
</td><td rowspan="1" colspan="1">Adeno (IM)</td><td rowspan="1" colspan="1">PAD/CLI (28)</td><td rowspan="1" colspan="1">No difference in amputation or death</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-26330040211070295"><p>ABI, ankle-brachial index; Adeno, adenoviral; ASO, arteriosclerosis
obliterans; BD, Buerger&#8217;s disease; CLI, critical limb ischemia; DM,
diabetes mellitus; DSA, digital subtraction angiography; FGF, fibroblast
growth factor; HGF, hepatocyte growth factor; HIF-1&#945;, hypoxia-inducible
factor 1&#945;; IA, intra-arterial; IM, intramuscular; MRA, magnetic
resonance angiography; PAD, peripheral arterial disease; pDNA, plasmid
DNA; QOL, quality of life; TBI, toe-brachial index; TcPO<sub>2</sub>,
transcutaneous oxygen pressure; VEGF, vascular endothelial growth
factor.</p></fn></table-wrap-foot></table-wrap><sec id="section12-26330040211070295"><title>Vascular endothelial growth factor</title><p>In the 1970s, Folkman hypothesized the existence of a soluble mediator of tumor
angiogenesis,<sup><xref rid="bibr37-26330040211070295" ref-type="bibr">37</xref></sup> and in 1989, Ferrara and Henzel isolated the factor now
known as VEGF in media conditioned by pituitary follicular cells.<sup><xref rid="bibr38-26330040211070295" ref-type="bibr">38</xref></sup> VEGF
expression is critical for embryonic development and postnatal
neovascularization. Preclinical studies in rabbits provided early evidence that
VEGF gene therapy can enhance angiogenesis following induction of hindlimb
ischemia.<sup><xref rid="bibr39-26330040211070295" ref-type="bibr">39</xref></sup> In 1998, Baumgartner <italic toggle="yes">et al.</italic><sup><xref rid="bibr40-26330040211070295" ref-type="bibr">40</xref></sup>
subsequently published a phase I trial of intramuscular (IM) administration of
naked DNA plasmid encoding the 165-amino-acid soluble isoform of human VEGF
(phVEGF<sub>165</sub>) in 10 limbs of nine patients with CLI and nonhealing
ulcers. Mean ABI improved from 0.33 to 0.48, ischemic ulcers improved in four of
seven limbs, and three patients originally recommended for below-knee amputation
achieved limb salvage. An additional seven limbs in six patients with Buerger&#8217;s
disease were treated in a separate study with similar results: an increase in
ABI of 0.10 in four of five patients with baseline ABI &lt;0.60, improved
angiographic findings, and salvage of six of seven limbs.<sup><xref rid="bibr41-26330040211070295" ref-type="bibr">41</xref></sup></p><p>Following Isner and Baumgartner&#8217;s pioneering work, several other studies of
VEGF-based gene therapy emerged. In 2003, Shyu <italic toggle="yes">et al.</italic><sup><xref rid="bibr42-26330040211070295" ref-type="bibr">42</xref></sup> published
their experience with phVEGF<sub>165</sub> in 24 limbs of 21 patients with rest
pain, 16 of whom also had nonhealing ulcers. Mean ABI improved from 0.58 to
0.72, ischemic ulcers improved in 75% of cases, and rest pain was relieved in
83% of patients. In a 2004 dose-finding study of IM VEGF<sub>165</sub> in nine
patients with debilitating PAD, seven of whom had Buerger&#8217;s disease, mean ABI
improved from 0.52 at baseline to 0.71 and 0.69 at 3 and 9 months
posttreatment.<sup><xref rid="bibr43-26330040211070295" ref-type="bibr">43</xref></sup> Of the seven patients with ischemic ulcers, two had
complete resolution and another two had improvement in ulcer size. Digital
subtraction angiography (DSA) also demonstrated increased collateral density in
six of nine patients at 3 months posttreatment and ischemic pain improved in
most patients. Of note, both studies reported transient leg edema in six of 24
limbs and three of nine patients, respectively.</p><p>In randomized studies, VEGF-based plasmid therapy has yielded more modest
benefit. In 2002, M&#228;kinen <italic toggle="yes">et al.</italic><sup><xref rid="bibr44-26330040211070295" ref-type="bibr">44</xref></sup> published a trial of
intra-arterial (IA) <italic toggle="yes">VEGF</italic> gene therapy administered at time of
angioplasty either as naked plasmid or adenoviral vector. Three months after
treatment, DSA revealed improved vascularity in both VEGF-treated groups
compared with placebo, but there were no significant difference in hemodynamic
parameters or amputation rate. In a RCT of phVEGF<sub>165</sub> in 54 diabetic
patients with CLI, Kusumanto <italic toggle="yes">et al.</italic><sup><xref rid="bibr45-26330040211070295" ref-type="bibr">45</xref></sup> found that 33% of
patients in the treatment group had a &gt;60% decrease in ulcer surface compared
with none of the patients in the control group; however, there was no
significant difference in major amputation rate at 100 days. Altogether, these
results indicate that VEGF therapy may improve wound healing rate with increase
in ABI on the order of 0.1 but no definitive clinical efficacy with regard to
amputation rate.</p></sec><sec id="section13-26330040211070295"><title>Hepatocyte growth factor</title><p>Hepatocyte growth factor (HGF) is secreted from stromal cells and acts via its
target receptor, cMet, on smooth muscle cells, fibroblasts, and ECs.<sup><xref rid="bibr46-26330040211070295" ref-type="bibr">46</xref></sup> As a
potent mitogen, HGF stimulates proliferation, motility, and morphogenesis of
these cells via paracrine and autocrine effects. In contrast to VEGF and FGF,
HGF also exerts anti-inflammatory and antifibrotic effects by means of epidermal
growth factor receptor (EGFR) downregulation.<sup><xref rid="bibr46-26330040211070295" ref-type="bibr">46</xref>,<xref rid="bibr47-26330040211070295" ref-type="bibr">47</xref></sup> Interest in HGF-based
angiogenic therapies stemmed from preclinical studies of HGF plasmid
transfection in rabbit and rat ischemia models that showed dose-dependent
increases in blood flow following treatment.<sup><xref rid="bibr48-26330040211070295" ref-type="bibr">48</xref></sup> In a subsequent trial of
<italic toggle="yes">HGF</italic> gene therapy in six patients with CLI secondary to
arteriosclerosis obliterans (ASO) and Buerger&#8217;s disease who were not candidates
for surgical revascularization,<sup><xref rid="bibr49-26330040211070295" ref-type="bibr">49</xref></sup> ABI improved from 0.43 at
baseline to 0.63 at 4 weeks and 0.60 at 8 weeks.</p><p>In 2011, Morishita <italic toggle="yes">et al.</italic><sup><xref rid="bibr50-26330040211070295" ref-type="bibr">50</xref></sup> published their initial
findings of <italic toggle="yes">HGF</italic> gene transfer in 22 patients with CLI. ABI
increased from 0.44 at baseline to 0.59 at 2 months and 0.65 at 6 months.
Walking distance also improved in all seven patients with severe claudication
and ulcer size decreased in 63.6% of patients with wounds. Treatment effect was
sustained in the 14 patients evaluated at 2-year follow-up as ABI remained
significantly elevated to 0.61.<sup><xref rid="bibr51-26330040211070295" ref-type="bibr">51</xref></sup> Importantly, no adverse
events related to the treatment were reported. In a follow-up analysis of all
Japanese trials, Morishita <italic toggle="yes">et al.</italic> reported that HGF therapy was
associated with improved wound healing, including complete ulcer resolution at
12 weeks in 48% of treated patients compared with 17% for placebo group. Rest
pain was also significantly improved but only in patients with Buerger&#8217;s disease
and diabetes.<sup><xref rid="bibr52-26330040211070295" ref-type="bibr">52</xref></sup></p><p>Placebo-controlled studies have confirmed some positive effects of HGF therapy
but failed to show benefit for other important clinical endpoints. In 2008,
Powell <italic toggle="yes">et al.</italic><sup><xref rid="bibr53-26330040211070295" ref-type="bibr">53</xref></sup> reported that high-dose
(4 mg IM at 0, 14, and 28 days) HGF plasmid therapy increased transcutaneous
oxygen pressure (TcPO<sub>2</sub>) in 100 patients with CLI and screening
TcPO<sub>2</sub>&#8196;&lt;&#8196;40 mmHg. However, there were no differences in ABI,
toe-brachial index (TBI), ulcer healing rate, or major amputation rate at 6
months. In a follow-up phase II study, the same group showed that TBI and pain
were significantly improved after HGF therapy in 21 patients with CLI compared
with six subjects assigned to placebo.<sup><xref rid="bibr54-26330040211070295" ref-type="bibr">54</xref></sup> However, wound healing,
amputation, and mortality rates were no different between the two groups.
Another randomized study of HGF plasmid injection in CLI found improved ulcer
size or rest pain in 70.4% of treated patients compared with 30.8% in placebo
group but no significant difference in change of ABI at 12 weeks between the two
groups.<sup><xref rid="bibr55-26330040211070295" ref-type="bibr">55</xref></sup> In all trials, HGF therapy demonstrated favorable
safety profile without significant treatment-related adverse events or cases of
peripheral edema as seen with VEGF therapy.</p></sec><sec id="section14-26330040211070295"><title>Fibroblast growth factor</title><p>FGF comprises a family of growth factors and signaling proteins that exert
mitogenic effects on a variety of cell types, thereby playing a role in
organogenesis and angiogenesis. FGF exists in two major forms, acidic FGF
(FGF-1) and basic FGF (FGF-2). In preclinical studies, both FGF-1 and FGF-2 were
able to improve limb revascularization in hamster and rabbit models of hindlimb
ischemia, respectively.<sup><xref rid="bibr56-26330040211070295" ref-type="bibr">56</xref>,<xref rid="bibr57-26330040211070295" ref-type="bibr">57</xref></sup> An early pilot study of nonviral FGF-1 (NV1FGF) in 51
patients with inoperable CLI found that therapy was well-tolerated and
associated with reduced pain and ulcer size and increased TcPO<sub>2</sub> and
ABI compared with pretreatment values.<sup><xref rid="bibr58-26330040211070295" ref-type="bibr">58</xref></sup> Subsequently, the phase 2
TALISMAN trial randomized 107 patients with no-option CLI and nonhealing ulcers
to NV1FGF or placebo. While ulcer healing rate, the primary endpoint, was no
different between the two groups, NV1FGF did reduce risk of major and any
amputation (hazard ratio (HR)&#8196;=&#8196;0.371 and 0.498, respectively).<sup><xref rid="bibr59-26330040211070295" ref-type="bibr">59</xref></sup> In
contrast, the phase 3 TAMARIS study randomized 525 patients with inoperable CLI
to NV1FGF or placebo and showed no difference in the combined primary endpoint,
time to major amputation on the treated leg or death.<sup><xref rid="bibr60-26330040211070295" ref-type="bibr">60</xref></sup> This discrepancy
regarding benefit of NV1FGF therapy on amputation rate may be explained by
unequal amputation rates in the placebo groups of these studies, which was more
than 50% in the initial TALISMAN study compared with 33% in the subsequent
TAMARIS trial.</p></sec></sec><sec id="section15-26330040211070295"><title>Cell therapies</title><p>While angiogenic factors are logical targets for therapeutic angiogenesis, cell-based
approaches provide another means of improving perfusion and wound healing in
ischemic tissue. Mononuclear cell (MNC) fractions derived from bone marrow or
peripheral blood contain cells of monocyte/macrophage lineage, as well as EPCs that
can directly participate in vasculogenesis. MSCs, however, are multipotent stromal
precursors that may differentiate into cells required for tissue regeneration, such
as ECs for angiogenesis and fibroblasts for wound healing, but primarily function
via paracrine mechanisms to prime the engrafted tissue for cell recruitment,
migration, and differentiation. In preclinical studies, both MNCs and MSCs have been
shown to induce neovascularization. For example, in a rat model of hindlimb
ischemia, perfusion index was significantly increased 3 weeks after IM injection of
either 5&#8196;&#215;&#8196;10<sup>6</sup> MSCs or MNCs compared with vehicle.<sup><xref rid="bibr63-26330040211070295" ref-type="bibr">63</xref></sup> Compared with
MNCs, however, MSCs were better able to improve perfusion index and capillary
density and were the only cell type capable of differentiation into vascular smooth
muscle cells and ECs.</p><sec id="section16-26330040211070295"><title>MNC therapy</title><p>Findings from the above and other preclinical studies paved the way for clinical
trials of cell-based therapeutics for patients with CLI due to atherosclerotic
PAD and Buerger&#8217;s disease (<xref rid="table2-26330040211070295" ref-type="table">Table 2</xref>). In the Therapeutic Angiogenesis by Cell Transplantation
(TACT) trial, 45 patients with bilateral lower limb ischemia received injection
of bone marrow&#8211;derived MNCs (BM-MNCs) into the left or right gastrocnemius
muscles and saline or peripheral blood MNCs (PB-MNCs) in the other limb as
control treatment in a within-patient trial design.<sup><xref rid="bibr64-26330040211070295" ref-type="bibr">64</xref></sup> Compared with those
receiving PB-MNCs, limbs treated with BM-MNCs demonstrated mean ABI increase of
0.09. Improvements were also noted in TcPO<sub>2</sub> measurements, rest pain,
new collateral formation, and pain-free walking time at 4 and 24 weeks
posttreatment. Long-term follow-up of 115 patients from TACT showed that
beneficial effects on pain, ulcer size, and pain-free walking distance were
durable up to 2 years after therapy.<sup><xref rid="bibr65-26330040211070295" ref-type="bibr">65</xref></sup> Importantly, patients
with Buerger&#8217;s disease fared better than those with atherosclerotic PAD: 3-year
amputation-free survival was 91% in patients with Buerger&#8217;s disease compared
with 60% in those with atherosclerotic PAD. Idei <italic toggle="yes">et
al.</italic><sup><xref rid="bibr66-26330040211070295" ref-type="bibr">66</xref></sup> found similar differences in their nonrandomized study
of BM-MNC transplantation in 51 patients with CLI, 26 of whom had Buerger&#8217;s
disease. Four-year amputation-free survival for patients with Buerger&#8217;s disease
was 95% after BM-MNC treatment and 6% in the control group, compared with 48%
and 0%, respectively, for patients with atherosclerotic PAD. Consistently, in
Buerger&#8217;s disease patients, ABI and TcPO<sub>2</sub> increased 1 month after
treatment and remained elevated at 3-year follow-up, while in PAD patients,
improvements in ABI and TcPO<sub>2</sub> observed at 1 month regressed to
baseline on long-term follow-up. The more durable benefits observed in Buerger&#8217;s
disease compared with atherosclerotic PAD may reflect the potentially reversible
autoimmune nature of the former compared with the cumulative, and more
permanent, plaque burden characteristic of the latter.</p><table-wrap position="float" id="table2-26330040211070295" orientation="portrait"><label>Table 2.</label><caption><p>Clinical trials of cell-based therapeutic angiogenesis in Buerger&#8217;s
disease and atherosclerotic PAD/CLI.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_26330040211070295-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Cell preparation</th><th align="left" rowspan="1" colspan="1">Population (<italic toggle="yes">N</italic>)</th><th align="left" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Tateishi-Yuyama <italic toggle="yes">et al.</italic><sup><xref rid="bibr64-26330040211070295" ref-type="bibr">64</xref></sup></td><td rowspan="1" colspan="1">2002</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">BM-MNC <italic toggle="yes">versus</italic> PB-MNC
<italic toggle="yes">versus</italic> saline</td><td rowspan="1" colspan="1">PAD/CLI, bilateral (45)</td><td rowspan="1" colspan="1">&#8593; ABI, TcPO<sub>2</sub>, pain-free walking time<break/>&#8595;
Rest pain</td></tr><tr><td rowspan="1" colspan="1">Durdu <italic toggle="yes">et al.</italic><sup><xref rid="bibr67-26330040211070295" ref-type="bibr">67</xref></sup></td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">BM-MNC</td><td rowspan="1" colspan="1">BD (28)</td><td rowspan="1" colspan="1">&#8593; ABI, wound healing, peak walking time, QOL<break/>&#8595; Rest
pain</td></tr><tr><td rowspan="1" colspan="1">Saito <italic toggle="yes">et al.</italic><sup><xref rid="bibr68-26330040211070295" ref-type="bibr">68</xref></sup></td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">BM-MNC</td><td rowspan="1" colspan="1">BD (14)</td><td rowspan="1" colspan="1">&#8593; Wound healing<break/>&#8595; Rest pain, ulcer size</td></tr><tr><td rowspan="1" colspan="1">Matoba <italic toggle="yes">et al.</italic><sup><xref rid="bibr65-26330040211070295" ref-type="bibr">65</xref></sup></td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">BM-MNC</td><td rowspan="1" colspan="1">PAD/CLI (74)<break/>BD (41)</td><td rowspan="1" colspan="1">&#8593; Wound healing, pain-free walking time<break/>&#8595; Rest
pain</td></tr><tr><td rowspan="1" colspan="1">Motukuru <italic toggle="yes">et al.</italic><sup><xref rid="bibr69-26330040211070295" ref-type="bibr">69</xref></sup></td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">BM-MNC</td><td rowspan="1" colspan="1">BD (36)</td><td rowspan="1" colspan="1">&#8593; ABI, TcPO<sub>2</sub>
<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Idei <italic toggle="yes">et al.</italic><sup><xref rid="bibr66-26330040211070295" ref-type="bibr">66</xref></sup></td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">BM-MNC</td><td rowspan="1" colspan="1">BD (26)<break/>PAD/CLI (25)</td><td rowspan="1" colspan="1">&#8593; ABI, TcPO<sub>2</sub> in BD patients only</td></tr><tr><td rowspan="1" colspan="1">Lu <italic toggle="yes">et al.</italic><sup><xref rid="bibr77-26330040211070295" ref-type="bibr">77</xref></sup></td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">BM-MNC <italic toggle="yes">versus</italic> BM-MSC
<italic toggle="yes">versus</italic> saline</td><td rowspan="1" colspan="1">PAD/CLI and DM (41)</td><td rowspan="1" colspan="1">&#8593; Pain-free walking time, ABI, TcPO<sub>2</sub> for
BM-MSC<break/>No difference in rest pain or amputation</td></tr><tr><td rowspan="1" colspan="1">Dash <italic toggle="yes">et al.</italic><sup><xref rid="bibr70-26330040211070295" ref-type="bibr">70</xref></sup></td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">BM-MSC</td><td rowspan="1" colspan="1">BD (9 BM-MSC, 9 placebo)<break/>Diabetic foot (3 BM-MSC, 3
placebo)</td><td rowspan="1" colspan="1">&#8593; Wound healing, pain-free walking distance</td></tr><tr><td rowspan="1" colspan="1">Gupta <italic toggle="yes">et al.</italic><sup><xref rid="bibr72-26330040211070295" ref-type="bibr">72</xref></sup></td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">BM-MSC</td><td rowspan="1" colspan="1">BD (36 low dose, 36 high dose)</td><td rowspan="1" colspan="1">&#8593; Wound healing, ABI, peak walking distance<break/>&#8595; Rest
pain</td></tr><tr><td rowspan="1" colspan="1">Lee <italic toggle="yes">et al.</italic><sup><xref rid="bibr74-26330040211070295" ref-type="bibr">74</xref></sup></td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">AD-MSC</td><td rowspan="1" colspan="1">BD (12)<break/>Diabetic foot (3)</td><td rowspan="1" colspan="1">&#8593; Wound healing, vascularity on DSA<break/>&#8595; Rest pain</td></tr><tr><td rowspan="1" colspan="1">Bura <italic toggle="yes">et al.</italic><sup><xref rid="bibr73-26330040211070295" ref-type="bibr">73</xref></sup></td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">AD-MSC</td><td rowspan="1" colspan="1">PAD/CLI (6)<break/>BD (1)</td><td rowspan="1" colspan="1">&#8593; Wound healing</td></tr><tr><td rowspan="1" colspan="1">Ra <italic toggle="yes">et al.</italic><sup><xref rid="bibr75-26330040211070295" ref-type="bibr">75</xref></sup></td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">AD-MSC</td><td rowspan="1" colspan="1">BD (17)</td><td rowspan="1" colspan="1">&#8593; Peak walking distance</td></tr><tr><td rowspan="1" colspan="1">Katagiri <italic toggle="yes">et al.</italic><sup><xref rid="bibr76-26330040211070295" ref-type="bibr">76</xref></sup></td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">ADRC</td><td rowspan="1" colspan="1">PAD/CLI (5)</td><td rowspan="1" colspan="1">&#8593; Wound healing, 6-min walking distance<break/>&#8595; Rest
pain</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-26330040211070295"><p>ABI, ankle-brachial index; AD-MSC, adipose-derived mesenchymal stem
cell; ADRC, adipose-derived regenerative cell; BD, Buerger&#8217;s
disease; BM-MNC, bone marrow-derived mononuclear cell; BM-MSC, bone
marrow-derived mesenchymal stem cell; CLI, critical limb ischemia;
DM, diabetes mellitus; DSA, digital subtraction angiography; PAD,
peripheral arterial disease; PB-MNC, peripheral blood mononuclear
cell; QOL, quality of life; TcPO<sub>2</sub>, transcutaneous oxygen
pressure.</p></fn></table-wrap-foot></table-wrap><p>Studies of cell-based therapy specifically enrolling patients with Buerger&#8217;s
disease have also yielded encouraging results. In 2006, Durdu <italic toggle="yes">et
al.</italic><sup><xref rid="bibr67-26330040211070295" ref-type="bibr">67</xref></sup> reported on their experience with autologous IM
injection of BM-MNCs in 28 patients with unilateral CLI secondary to Buerger&#8217;s
disease. By 6 months posttreatment, patients demonstrated significant
improvements in rest pain, peak walking time, and quality of life. Complete
ulcer healing was achieved in 83% of patients with wounds, while half of
patients had an increase in ABI &gt;0.15 and 78.5% demonstrated collateral
formation on DSA. In 2007, Saito <italic toggle="yes">et al.</italic><sup><xref rid="bibr68-26330040211070295" ref-type="bibr">68</xref></sup> published
their results of a nonrandomized study of autologous BM-MNC transplantation in
14 patients with ischemic rest pain or ulceration due to Buerger&#8217;s disease. Pain
scores improved from 5.4 at baseline to 2.5 at 4 weeks and 1.1 at 24 weeks. Of
the 19 ulcers in nine patients, 12 completely healed, two diminished in size,
and four increased in size by 24 weeks. In 2008, Motukuru <italic toggle="yes">et
al.</italic><sup><xref rid="bibr69-26330040211070295" ref-type="bibr">69</xref></sup> reported on 36 patients with inoperable Buerger&#8217;s
disease treated with IM injection of autologous BM-MNCs. Three patients (12%)
required major amputation by 6 months posttreatment. ABI and TcPO<sub>2</sub>
significantly improved by 0.14 and 52 mmHg, respectively, as did pain measured
on a visual analogue scale. In all studies, no treatment-related complications
were reported.</p></sec><sec id="section17-26330040211070295"><title>MSC therapy</title><p>In 2009, Dash <italic toggle="yes">et al.</italic> published the only randomized study of
autologous bone marrow&#8211;derived MSC (BM-MSC) administration in 24 patients with
nonhealing ulcers of the lower extremities.<sup><xref rid="bibr70-26330040211070295" ref-type="bibr">70</xref>,<xref rid="bibr71-26330040211070295" ref-type="bibr">71</xref></sup> In the 18 patients with a
diagnosis of Buerger&#8217;s disease, ulcer area decreased by 71% in the treatment
group compared with 23% in the control group by 12-week follow-up. Pain-free
walking distance also improved from 38.3 m to 284.4 in the treatment group
compared with an increase from 35.7 to 78.2 m in the control group. In 2017, a
nonrandomized dose-finding study of allogenic BM-MSC treatment in 72 patients
with Buerger&#8217;s disease found that ulcer healing and rest pain reduction rates
were significantly better in the 2 million cells/kg group compared with 1
million cells/kg and standard of care groups; however, there was no significant
difference in collateral formation on magnetic resonance angiography (MRA) or
amputation-free survival.<sup><xref rid="bibr72-26330040211070295" ref-type="bibr">72</xref></sup></p><p>Adipose tissue is another source of MSCs for autologous transplantation and early
pilot studies demonstrated feasibility and safety of this technique.<sup><xref rid="bibr73-26330040211070295" ref-type="bibr">73</xref></sup> In one
series, seven of 12 patients with Buerger&#8217;s disease noted improved ulcer
appearance after AD-MSC treatment,<sup><xref rid="bibr74-26330040211070295" ref-type="bibr">74</xref></sup> while in another, walking
distance increased from 300 m at baseline to 397 m 24 weeks after treatment in
17 patients with severe Buerger&#8217;s disease.<sup><xref rid="bibr75-26330040211070295" ref-type="bibr">75</xref></sup> In TACT-ADRC, five
patients with CLI received autologous IM injection of adipose-derived
regenerative cells (ADRCs) and noted significant improvements in pain and 6-min
walking distance with no amputations during the 6-month study period.<sup><xref rid="bibr76-26330040211070295" ref-type="bibr">76</xref></sup>
Interestingly, ADRCs increased the number of circulating progenitor cells
(CD34<sup>+</sup>/CD133<sup>+</sup>) and decreased the relative expression
of VEGF-A<sub>165</sub>b, an antiangiogenic alternative splice variant of
VEGF-A. In comparing different cell preparations, a <italic toggle="yes">Cochrane</italic>
review pooling results from seven RCTs (359 patients) of autologous cell-based
therapy in no-option CLI found no difference in outcomes between BM-MNC and
mobilized peripheral blood stem cell (mPBSC) treatment, or between IM or IA
injection.<sup><xref rid="bibr30-26330040211070295" ref-type="bibr">30</xref></sup> However, in one RCT comparing BM-MSCs and BM-MNCs in 41
patients with diabetes and CLI, BM-MSCs were better able to induce limb
reperfusion and ulcer healing with significantly greater increase in ABI,
TcPO<sub>2</sub>, and pain-free walking time.<sup><xref rid="bibr77-26330040211070295" ref-type="bibr">77</xref></sup></p></sec></sec><sec id="section18-26330040211070295"><title>Adverse effects and limitations of current angiogenic therapies</title><p>In all examined studies, the most prevalent treatment-related side effects have been
limited to injection site reactions which are generally self-limited and managed
conservatively. In the case of <italic toggle="yes">VEGF</italic> gene therapy, specifically,
there are several reports of peripheral edema as a complication of both naked
plasmid and adenoviral delivery mechanisms. This complication has not been observed
with other gene therapies. Potential adverse effects of angiogenic therapy include
proliferative retinopathy, arteriovenous malformation, and neoplasia; however, none
of the available studies reported significant associations between either gene or
cell therapy and such complications. Nevertheless, patients should be screened for
malignancy and retinopathy and counseled on these potential risks prior to
initiating angiogenic therapy.</p><p>As research into therapeutic angiogenesis has progressed from small observational
studies to larger prospective cohort and randomized trials, several meta-analyses
have collectively analyzed safety and efficacy data for gene and cell-based
therapeutics in CLI. Recently, a <italic toggle="yes">Cochrane</italic> meta-analysis of 17 RCTs
evaluated efficacy of various gene therapies for intermittent claudication and CLI
in 1988 participants.<sup><xref rid="bibr78-26330040211070295" ref-type="bibr">78</xref></sup> Pooled data showed no clear difference between gene therapy
and placebo with regard to amputation-free survival and all-cause mortality.
Although there was limited evidence for improved ulcer healing with gene therapy,
the authors found no difference in pain scores or change in ABI between treatment
and control groups. In subgroup analyses, there was no difference in outcomes
between gene therapy and placebo according to PAD severity (claudication
<italic toggle="yes">versus</italic> CLI), vector type (plasmid <italic toggle="yes">versus</italic>
viral), or gene encoded.</p><p>Results from meta-analyses of cell-based therapies have also been mixed. Multiple
studies using data from randomized as well as nonrandomized and uncontrolled trials
have reported favorable effects on amputation and ulcer healing rates with cell
therapy.<sup><xref rid="bibr79-26330040211070295" ref-type="bibr">79</xref>
<xref rid="bibr80-26330040211070295" ref-type="bibr"/><xref rid="bibr81-26330040211070295" ref-type="bibr"/>&#8211;<xref rid="bibr82-26330040211070295" ref-type="bibr">82</xref></sup> However, when only randomized
studies are included, the benefits are more marginal. For example, Peeters Weem
<italic toggle="yes">et al.</italic><sup><xref rid="bibr83-26330040211070295" ref-type="bibr">83</xref></sup> found significantly improved ABI (mean difference 0.11),
TcPO<sub>2</sub>, and pain scores with cell therapy, but no significant
differences in primary outcome measures of amputation, survival, and amputation-free
survival in 499 CLI patients from 10 studies. Another meta-analysis of 12 randomized
trials including 510 CLI patients initially found reduced major amputation risk
(risk ratio (RR)&#8196;=&#8196;0.58) with cell therapy, but the results became nonsignificant
when only placebo-controlled studies were analyzed.<sup><xref rid="bibr84-26330040211070295" ref-type="bibr">84</xref></sup> Similarly, an analysis of 774
CLI patients from 16 RCTs found reduced odds of major amputation (odds ratio
(OR)&#8196;=&#8196;0.54) and improved ulcer healing (OR&#8196;=&#8196;2.90) with cell therapy, but again,
all differences became nonsignificant when only placebo-controlled trials were
reanalayzed.<sup><xref rid="bibr85-26330040211070295" ref-type="bibr">85</xref></sup></p></sec><sec id="section19-26330040211070295"><title>Emerging trends in therapeutic angiogenesis</title><p>To date, clinical trials of therapeutic angiogenesis have primarily focused on DNA
plasmids encoding known angiogenic factors or cell-based treatments using MNCs or
MSCs. Improving upon these treatments and developing novel therapies for CLI hinges
on an understanding of the precise mechanisms involved in vasculogenesis and
angiogenesis. The recruitment of EPCs and MSCs from the bone marrow to areas of
ischemia and wound healing is known as the process of homing. Homing of EPCs and
MSCs is subject to regulation by many factors and mediated by a panel of cell
adhesion molecules (CAMs). Under pathological conditions, such as tissue injury,
ischemia, and inflammation, the normally quiescent endothelium is stimulated to
express a variety of CAMs and secrete cytokines/chemokines to recruit the necessary
immune-modulatory and repair cells. Importantly, hypoxia-inducible factor 1&#945;
(HIF-1&#945;) expression induces secretion of various cytokines/chemokines, including
stromal cell-derived factor 1 alpha (SDF-1&#945;&amp;x41;, TNF-&#945;, and IL-1.<sup><xref rid="bibr86-26330040211070295" ref-type="bibr">86</xref>,<xref rid="bibr87-26330040211070295" ref-type="bibr">87</xref></sup> Consistently,
in preclinical studies, increasing tissue microenvironment levels of SDF-1&#945; in
diabetic mice has been shown to improve wound healing rates.<sup><xref rid="bibr86-26330040211070295" ref-type="bibr">86</xref></sup></p><sec id="section20-26330040211070295"><title>E-selectin for therapeutic angiogenesis</title><p>In particular, SDF-1&#945; upregulates expression of E-selectin and its ligands on
ECs.<sup><xref rid="bibr86-26330040211070295" ref-type="bibr">86</xref>,<xref rid="bibr88-26330040211070295" ref-type="bibr">88</xref></sup> E-selectin is an inducible CAM expressed on endothelium
which binds P-selectin glycoproteins-1 (PSGL-1/CD162), CD44, and E-selectin
ligand (ESL-1) presented on the surface of circulating cells. In this way,
E-selectin serves as endothelial docking sites to anchor circulating stem and
progenitor cells, such as EPCs, that reciprocally express E-selectin ligands. In
murine models, levels of membrane-bound E-selectin peak 12 h after ischemic
insult, while serum levels of soluble E-selectin remain elevated for up to 7
days.<sup><xref rid="bibr89-26330040211070295" ref-type="bibr">89</xref></sup> Homing of EPCs is impaired in E-selectin knock-out mice
(Esel<sup>&#8722;/&#8722;</sup>) but can be rescued by IV administration of
sE-selectin.<sup><xref rid="bibr89-26330040211070295" ref-type="bibr">89</xref></sup> In addition, Esel<sup>&#8722;/&#8722;</sup> mice demonstrate
impaired EPC homing to wound tissue, slower wound closure rate, and delayed
recovery of hindlimb perfusion following femoral artery ligation.<sup><xref rid="bibr88-26330040211070295" ref-type="bibr">88</xref></sup>
E-selectin-mediated cell&#8211;cell interactions between MSCs and ECs are also
critical events for MSC-induced angiogenesis and tissue repair.<sup><xref rid="bibr86-26330040211070295" ref-type="bibr">86</xref>,<xref rid="bibr90-26330040211070295" ref-type="bibr">90</xref>,<xref rid="bibr91-26330040211070295" ref-type="bibr">91</xref></sup> While the
above effects of E-selectin reflect cell&#8211;cell interactions mediated by the
protein&#8217;s extracellular domain, we have unpublished gene profiling data from
ischemic hindlimbs treated with IM E-selectin gene therapy indicating that,
compared with control vector, E-selectin overexpression leads to intense
upregulation of dozens of pro-angiogenesis genes while having an overall
inhibitory or cooling effect on the majority of pro-inflammatory genes.
Altogether, these findings illustrate the role of E-selectin in the tissue
response to ischemia and present a novel target for therapeutic angiogenesis in
CLI and Buerger&#8217;s disease.</p></sec><sec id="section21-26330040211070295"><title>Viral vectors for gene delivery</title><p>To date, most growth factor&#8211;based therapeutics have been formulated as naked
DNA-encoding plasmids. Viral vectors provide another means of increasing local
expression of angiogenic factors, and adenovirus, specifically, has been used in
studies of therapeutic angiogenesis. A randomized, double-blind,
placebo-controlled trial assessed the efficacy of Ad2/HIF-1&#945;/VP16, an adenoviral
construct encoding a constitutively active form of HIF-1&#945;, in 34 no-option CLI
patients.<sup><xref rid="bibr62-26330040211070295" ref-type="bibr">62</xref></sup> Injection site reactions and peripheral edema were the
most common side effects. After 1 year, complete resolution of rest pain
occurred in 14 of 21 patients and complete ulcer healing in 5 of 8 patients
alive with the index limb. Another RCT evaluated adenoviral delivery of VEGF but
failed to show benefit in 105 patients with unilateral exercise-limiting
claudication.<sup><xref rid="bibr61-26330040211070295" ref-type="bibr">61</xref></sup> Specifically, there was no significant difference
between treatment and placebo groups with regards to change in peak walking
time, the primary endpoint, or secondary endpoints of ABI, claudication onset
time, and quality of life. In addition, AdVEGF121 therapy was associated with
peripheral edema in the treated limb. Recently, the Food and Drug Administration
(FDA) approved two gene therapy products, Luxturna&#174; (voretigene neparvovec) and
Zolgensma&#174; (onasemnogene abeparvovec-xioi), which are now available for the
treatment of Leber congenital amaurosis and spinal muscular atrophy,
respectively. These treatments employ another gene delivery vector,
adeno-associated virus (AAV), which has a more favorable safety profile than
adenovirus. In comparison with adenoviral vectors, which activate the NF-&#954;B
pathway, AAV does not promote a strong immune response to virally encoded
proteins and provides long-lasting stable tissue transduction up to 2
years.<sup><xref rid="bibr92-26330040211070295" ref-type="bibr">92</xref></sup> These features make AAV an interesting gene delivery
platform for future clinical trials of therapeutic angiogenesis.</p></sec><sec id="section22-26330040211070295"><title>E-selectin/adeno-associated virus gene therapy</title><p>As discussed, the adhesion molecule E-selectin and its ligands play a crucial
role in the response to tissue ischemia and injury by priming the endothelium to
recruit necessary repair cells from the circulation. E-selectin overexpression
in ischemic hindlimb tissue also causes activation of secondary paracrine
signaling cascades that augment tissue angiogenesis and downregulate
inflammation. With the goal of leveraging these actions of E-selectin for
therapeutic benefit, we have tested the feasibility, safety, and efficacy of IM
E-selectin/AAV gene therapy in murine hindlimb ischemia and gangrene models
(<xref rid="table3-26330040211070295" ref-type="table">Table
3</xref>).<sup><xref rid="bibr93-26330040211070295" ref-type="bibr">93</xref>,<xref rid="bibr94-26330040211070295" ref-type="bibr">94</xref></sup> In summary, treating hindlimb muscle with
E-selectin/AAV results in significantly improved recovery of hindlimb perfusion
following ischemic insult. Clinically, enhanced blood flow to the hindlimb
translates into more rapid wound healing, reduced gangrene severity, and
increased exercise capacity. On DiI perfusion imaging, mice treated with
E-selectin/AAV demonstrate plusher capillary networks surrounding the wound bed
and murine footpad. Importantly, systemic D-dimer levels are not increased from
baseline and no microvascular thrombosis or T cell infiltration is noted on
histological analysis, indicating that local IM E-selectin gene therapy does not
have a prothrombotic effect or cause a lymphocytic reaction. Altogether, these
preclinical results pave the way for development of E-selectin-based angiogenic
therapies.</p><table-wrap position="float" id="table3-26330040211070295" orientation="portrait"><label>Table 3.</label><caption><p>Emerging modalities for therapeutic angiogenesis in preclinical
stages.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_26330040211070295-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Model</th><th align="left" rowspan="1" colspan="1">Therapy</th><th align="left" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Castilla <italic toggle="yes">et al.</italic><sup><xref rid="bibr95-26330040211070295" ref-type="bibr">95</xref></sup></td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">Mouse, diabetic wound</td><td rowspan="1" colspan="1">SDF-1&#945;-primed-BMDSC</td><td rowspan="1" colspan="1">&#8593; Wound healing, EPC recruitment, wound
neovascularization</td></tr><tr><td rowspan="1" colspan="1">Ranghino <italic toggle="yes">et al.</italic><sup><xref rid="bibr99-26330040211070295" ref-type="bibr">99</xref></sup></td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">Mouse, hindlimb ischemia</td><td rowspan="1" colspan="1">EPC-derived microvesicles</td><td rowspan="1" colspan="1">&#8593; Perfusion (LDI), capillary density</td></tr><tr><td rowspan="1" colspan="1">Liu <italic toggle="yes">et al.</italic><sup><xref rid="bibr91-26330040211070295" ref-type="bibr">91</xref></sup></td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">Mouse, diabetic wound</td><td rowspan="1" colspan="1">E-selectin nanocarrier-coated MSC</td><td rowspan="1" colspan="1">&#8593; Wound healing</td></tr><tr><td rowspan="1" colspan="1">Komaki <italic toggle="yes">et al.</italic><sup><xref rid="bibr100-26330040211070295" ref-type="bibr">100</xref></sup></td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">Mouse, auricle ischemia</td><td rowspan="1" colspan="1">MSC-derived exosomes</td><td rowspan="1" colspan="1">&#8593; Perfusion (LDI)</td></tr><tr><td rowspan="1" colspan="1">Parikh <italic toggle="yes">et al.</italic><sup><xref rid="bibr93-26330040211070295" ref-type="bibr">93</xref></sup></td><td rowspan="1" colspan="1">2018</td><td rowspan="1" colspan="1">Mouse, hindlimb ischemia</td><td rowspan="1" colspan="1">E-selectin/AAV2/9</td><td rowspan="1" colspan="1">&#8593; Perfusion (LDI), wound healing</td></tr><tr><td rowspan="1" colspan="1">Quiroz <italic toggle="yes">et al.</italic><sup><xref rid="bibr94-26330040211070295" ref-type="bibr">94</xref></sup></td><td rowspan="1" colspan="1">2021</td><td rowspan="1" colspan="1">Mouse, hindlimb gangrene</td><td rowspan="1" colspan="1">E-selectin/AAV2/9</td><td rowspan="1" colspan="1">&#8593; Perfusion (LDI), exercise capacity<break/>&#8595; Tissue
loss</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-26330040211070295"><p>AAV, adeno-associated virus; BMDSC, bone marrow-derived stem cell;
EPC, endothelial progenitor cell; LDI, laser Doppler imaging; MSC,
mesenchymal stem cell; SDF-1&#945;, stromal cell-derived factor 1
alpha.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section23-26330040211070295"><title>Enhanced cell-based therapies</title><p>In clinical studies, cell-based therapies have shown potential for improving
ulcer healing, pain, and walking capacity, but placebo-controlled trials have
reported modest to no benefit on hemodynamic parameters and amputation rate.
Importantly, these studies have only employed unmodified, unstimulated MSCs or
MNCs isolated from the circulation, bone marrow, or adipose tissue. One
potential avenue for increasing the potency of these therapies involves priming
stem cells with various growth or mitogenic factors in culture prior to
transplantation. For example, in mice, priming bone marrow&#8211;derived stem cells
(BMDSCs) with SDF-1&#945; prior to intradermal injection increases wound healing
potential compared with unstimulated BMDSCs.<sup><xref rid="bibr95-26330040211070295" ref-type="bibr">95</xref></sup> There is also evidence
that AAV-induced expression of E-selectin in MSCs, which do not normally express
this adhesion molecule, can increase proliferative and anti-inflammatory
properties of these cells, translating to improved recovery of limb perfusion
and function in murine hindlimb ischemia models. Similarly, in rat myocardial
infarction models, <italic toggle="yes">HGF</italic> gene-engineered myoblasts exhibit
improved engraftment and ultimately lead to better recovery of cardiac
function.<sup><xref rid="bibr96-26330040211070295" ref-type="bibr">96</xref></sup> Rather than directly administering modified stem cells,
BM-MSCs can also be primed in co-culture with genetically modified
HGF-expressing MSCs.<sup><xref rid="bibr97-26330040211070295" ref-type="bibr">97</xref></sup> In the form of a cardiac patch, conditioned BM-MSC
demonstrated improved repair of infarcted myocardium compared with unstimulated
BM-MSC. In another approach, coating MSCs with E-selectin/dendrimer nanocarrier
can specifically direct these cells from the circulation to activated
endothelium in ischemic or inflamed tissue, thereby improving wound healing
rate.<sup><xref rid="bibr91-26330040211070295" ref-type="bibr">91</xref></sup></p></sec><sec id="section24-26330040211070295"><title>Exosomes and cell-free approaches</title><p>Despite promising preclinical and clinical results, there remain several inherent
limitations to cell-based therapies. Autologous stem cell treatments raise the
theoretical risk of unmitigated cell proliferation and potential malignant
transformation, while allogeneic transplantation carries additional risk of
immune rejection. In addition, there is evidence that cells isolated from
patients with Buerger&#8217;s disease, diabetes, or other forms of PAD and CLI have
poorer angiogenic potential compared with cells from healthy subjects, which
further limits <italic toggle="yes">in vivo</italic> efficacy.<sup><xref rid="bibr74-26330040211070295" ref-type="bibr">74</xref></sup> With this in mind,
multiple studies have observed that conditioned media, or the supernatant
collected from cell culture plates after incubation for a period of time, can
alone exert angiogenic and antiapoptotic effects <italic toggle="yes">in
vitro</italic>.<sup><xref rid="bibr98-26330040211070295" ref-type="bibr">98</xref></sup> In particular, microvesicles derived from EPCs have
been shown to improve neovascularization in a murine hindlimb ischemia
model,<sup><xref rid="bibr99-26330040211070295" ref-type="bibr">99</xref></sup> whereas exosomes isolated from MSC cultures have been
shown to improve neovascularization in a murine model of auricle
ischemia<sup><xref rid="bibr100-26330040211070295" ref-type="bibr">100</xref></sup> and fracture healing in a rat model of
nonunion.<sup><xref rid="bibr101-26330040211070295" ref-type="bibr">101</xref></sup> Exosomes are small vesicles (30&#8211;150 nm) secreted by
MSCs and other cell types to deliver protein, RNA, and cytokines/chemokines that
stimulate biological functions by paracrine mechanisms. Exosomes lack major
histocompatibility complex (MHC) and are therefore nonimmunogenic. This is
advantageous as exosome extracted from cells isolated from unrelated healthy
donors could be administered to patients in an allogeneic manner without concern
for immune reaction. In addition, exosomes can be concentrated and then stored
or transported with greater logistical ease than the cell cultures they are
derived from.</p></sec></sec><sec id="section25-26330040211070295"><title>Conclusion</title><p>While increasingly rare in the West, Buerger&#8217;s disease represents an important form
of PAD worldwide with significant morbidity for patients afflicted with the disease.
Despite remarkable advances in drug development and surgical technology over the
past century, the treatment landscape for Buerger&#8217;s disease remains limited. Current
medical therapies have little to no benefit in randomized studies, and surgical
revascularization, both open and endovascular, is not a viable option for many
patients. As such, noninvasive regenerative approaches are attractive avenues for
clinical research. Multiple prospective studies have reported positive effects of
gene and cell therapies on limb pain, walking distance, and ulcer healing rates in
patients with CLI and Buerger&#8217;s disease. However, there is still a lack of strong
evidence for improvement in hemodynamic parameters or amputation-free survival in
randomized trials. For these reasons, optimizing existing technologies and exploring
new targets for therapeutic angiogenesis are important strategies for helping
patients with Buerger&#8217;s disease, and the larger population of no-option CLI
patients. E-selectin is one such possible target, with multiple preclinical studies
having elucidated its role in angiogenesis and efficacy in diabetic wound healing
and reversal of hindlimb ischemia. Inducing cellular expression of E-selectin, or
other CAMs and growth factors, may be used to potentiate <italic toggle="yes">in vivo</italic>
angiogenic effect of some cell-based therapies. Alternatively, cell-free
preparations of concentrated MSC-derived exosomes may deliver angiogenic effect
while avoiding complications of naked plasmids, viral vectors, and cell-based
therapies. In summary, the treatments reviewed herein represent some of the most
promising emerging modalities for therapeutic angiogenesis that may someday be
readily available to relieve ischemic pain, heal ulcers, prevent major amputation,
and improve quality of life in patients with Buerger&#8217;s disease and no-option
CLI.</p></sec></body><back><ack><p>All figures were created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></ack><fn-group><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Antoine J. Ribieras:</bold> Conceptualization, Investigation, Methodology,
Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p><p><bold>Yulexi Y. Ortiz:</bold> Conceptualization, Writing &#8211; review &amp;
editing.</p><p><bold>Zhao-Jun Liu:</bold> Conceptualization, Methodology, Supervision, Writing &#8211;
review &amp; editing.</p><p><bold>Omaida C. Velazquez:</bold> Conceptualization, Methodology, Supervision,
Writing &#8211; review &amp; editing.</p></fn><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: The E-selectin
gene modification technologies described were developed in our research
laboratory and patented/licensed by the University of Miami. This technology is
currently under preclinical development by Ambulero Inc., a new start-up company
out of the University of Miami that focuses on developing new vascular
treatments for ischemic conditions. Co-authors, Z.J.L. and O.C.V., serve as
consultants and scientific and medical advisory officers.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or
publication of this article.</p></fn><fn fn-type="other"><p><bold>Ethics statement:</bold> Animal experiments performed at the University of Miami were approved by the
University of Miami Institutional Animal Care and Use Committee (IACUC) under
protocol 19-163. Ethical approval and informed consent were not required for the
remainder of this review.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Antoine J. Ribieras <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_26330040211070295-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-7380-3435" ext-link-type="uri">https://orcid.org/0000-0001-7380-3435</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-26330040211070295"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buerger</surname><given-names>L</given-names></name></person-group>. <article-title>Landmark publication from the American Journal
of the Medical Sciences, &#8216;thrombo-angiitis obliterans: a study of the
vascular lesions leading to presenile spontaneous gangrene&#8217;.
1908</article-title>. <source>Am J Med Sci</source><year>2009</year>; <volume>337</volume>:
<fpage>274</fpage>&#8211;<lpage>284</lpage>.<pub-id pub-id-type="pmid">19365174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MAJ.0b013e31818c8bc9</pub-id></mixed-citation></ref><ref id="bibr2-26330040211070295"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera-Chavarr&#237;a</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Brenes-Guti&#233;rrez</surname><given-names>JD</given-names></name></person-group>. <article-title>Thromboangiitis obliterans (Buerger&#8217;s
disease)</article-title>. <source>Ann Med Surg</source><year>2016</year>; <volume>7</volume>:
<fpage>79</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amsu.2016.03.028</pub-id><pub-id pub-id-type="pmcid">PMC4840397</pub-id><pub-id pub-id-type="pmid">27144003</pub-id></mixed-citation></ref><ref id="bibr3-26330040211070295"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarides</surname><given-names>MK</given-names></name><name name-style="western"><surname>Georgiadis</surname><given-names>GS</given-names></name><name name-style="western"><surname>Papas</surname><given-names>TT</given-names></name></person-group>, <etal>et al</etal><article-title>Diagnostic criteria and treatment of Buerger&#8217;s disease: a
review</article-title>. <source>Int J Low Extrem Wounds</source><year>2006</year>; <volume>5</volume>:
<fpage>89</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">16698911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1534734606288817</pub-id></mixed-citation></ref><ref id="bibr4-26330040211070295"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olin</surname><given-names>JW</given-names></name></person-group>. <article-title>Thromboangiitis obliterans (Buerger&#8217;s
disease)</article-title>. <source>N Engl J Med</source><year>2000</year>; <volume>343</volume>:
<fpage>864</fpage>&#8211;<lpage>869</lpage>.<pub-id pub-id-type="pmid">10995867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200009213431207</pub-id></mixed-citation></ref><ref id="bibr5-26330040211070295"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>T</given-names></name><name name-style="western"><surname>Shigematsu</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal><article-title>Current trends in epidemiology and clinical features of
thromboangiitis obliterans in Japan &#8211; a nationwide survey using the medical
support system database</article-title>. <source>Circ J</source><year>2020</year>; <volume>84</volume>:
<fpage>1786</fpage>&#8211;<lpage>1796</lpage>.<pub-id pub-id-type="pmid">32879220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.CJ-19-1165</pub-id></mixed-citation></ref><ref id="bibr6-26330040211070295"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olin</surname><given-names>JW</given-names></name><name name-style="western"><surname>Shih</surname><given-names>A</given-names></name></person-group>. <article-title>Thromboangiitis obliterans (Buerger&#8217;s
disease)</article-title>. <source>Curr Opin Rheumatol</source><year>2006</year>; <volume>18</volume>:
<fpage>18</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">16344615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.bor.0000198000.58073.aa</pub-id></mixed-citation></ref><ref id="bibr7-26330040211070295"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olin</surname><given-names>JW</given-names></name><name name-style="western"><surname>Young</surname><given-names>JR</given-names></name><name name-style="western"><surname>Graor</surname><given-names>RA</given-names></name></person-group>, <etal>et al</etal><article-title>The changing clinical spectrum of thromboangiitis obliterans
(Buerger&#8217;s disease)</article-title>. <source>Circulation</source><year>1990</year>; <volume>82</volume>(<issue>Suppl. 5</issue>):
<fpage>IV3</fpage>&#8211;<lpage>IV8</lpage>.<pub-id pub-id-type="pmid">2225420</pub-id></mixed-citation></ref><ref id="bibr8-26330040211070295"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Joncour</surname><given-names>A</given-names></name><name name-style="western"><surname>Soudet</surname><given-names>S</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Long-term outcome and prognostic factors of complications in
thromboangiitis obliterans (Buerger&#8217;s disease): a multicenter study of 224
patients</article-title>. <source>J Am Heart Assoc</source><year>2018</year>; <volume>7</volume>: <fpage>e010677</fpage>.<pub-id pub-id-type="pmid">30571594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.118.010677</pub-id><pub-id pub-id-type="pmcid">PMC6405548</pub-id></mixed-citation></ref><ref id="bibr9-26330040211070295"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aerbajinai</surname><given-names>W</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>T</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>HLA class II DNA typing in Buerger&#8217;s disease</article-title>.
<source>Int J Cardiol</source><year>1996</year>; <volume>54</volume>(<issue>Suppl.</issue>):
<fpage>S197</fpage>&#8211;<lpage>S202</lpage>.<pub-id pub-id-type="pmid">9119524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-5273(96)88790-0</pub-id></mixed-citation></ref><ref id="bibr10-26330040211070295"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaini</surname><given-names>R</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>S</given-names></name><name name-style="western"><surname>Khazanchi</surname><given-names>RK</given-names></name></person-group>, <etal>et al</etal><article-title>Immunogenetic analysis of Buerger&#8217;s disease in
India</article-title>. <source>Int J Cardiol</source><year>1998</year>; <volume>66</volume>:
<fpage>283</fpage>&#8211;<lpage>285</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-5273(98)00180-6</pub-id><pub-id pub-id-type="pmid">9951831</pub-id></mixed-citation></ref><ref id="bibr11-26330040211070295"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapouri-Moghaddam</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>HR</given-names></name></person-group>, <etal>et al</etal><article-title>The association of HLA-A, B and DRB1 with Buerger&#8217;s
disease</article-title>. <source>Rep Biochem Mol Biol</source><year>2019</year>; <volume>8</volume>:
<fpage>153</fpage>&#8211;<lpage>160</lpage>.<pub-id pub-id-type="pmid">31832439</pub-id><pub-id pub-id-type="pmcid">PMC6844607</pub-id></mixed-citation></ref><ref id="bibr12-26330040211070295"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>XL</given-names></name><name name-style="western"><surname>Law</surname><given-names>BYK</given-names></name><name name-style="western"><surname>de Seabra Rodrigues Dias</surname><given-names>IR</given-names></name></person-group>, <etal>et al</etal><article-title>Pathogenesis of thromboangiitis obliterans: gene polymorphism and
immunoregulation of human vascular endothelial cells</article-title>.
<source>Atherosclerosis</source><year>2017</year>; <volume>265</volume>:
<fpage>258</fpage>&#8211;<lpage>265</lpage>.<pub-id pub-id-type="pmid">28864202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2017.08.009</pub-id></mixed-citation></ref><ref id="bibr13-26330040211070295"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dellalibera-Joviliano</surname><given-names>R</given-names></name><name name-style="western"><surname>Joviliano</surname><given-names>EE</given-names></name><name name-style="western"><surname>Silva</surname><given-names>JS</given-names></name></person-group>, <etal>et al</etal><article-title>Activation of cytokines corroborate with development of
inflammation and autoimmunity in thromboangiitis obliterans
patients</article-title>. <source>Clin Exp Immunol</source><year>2012</year>; <volume>170</volume>:
<fpage>28</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">22943198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2249.2012.04624.x</pub-id><pub-id pub-id-type="pmcid">PMC3444714</pub-id></mixed-citation></ref><ref id="bibr14-26330040211070295"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shionoya</surname><given-names>S</given-names></name></person-group>. <article-title>Diagnostic criteria of Buerger&#8217;s
disease</article-title>. <source>Int J Cardiol</source><year>1998</year>; <volume>66</volume>:
<fpage>243</fpage>&#8211;<lpage>246</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-5273(98)00175-2</pub-id><pub-id pub-id-type="pmid">9951826</pub-id></mixed-citation></ref><ref id="bibr15-26330040211070295"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papa</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Rabi</surname><given-names>I</given-names></name><name name-style="western"><surname>Adar</surname><given-names>R</given-names></name></person-group>. <article-title>A point scoring system for the clinical
diagnosis of Buerger&#8217;s disease</article-title>. <source>Eur J Vasc Endovasc
Surg</source><year>1996</year>; <volume>11</volume>:
<fpage>335</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">8601245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1078-5884(96)80081-5</pub-id></mixed-citation></ref><ref id="bibr16-26330040211070295"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>JL</given-names></name><name name-style="western"><surname>Porter</surname><given-names>JM</given-names></name></person-group>. <article-title>Buerger&#8217;s disease (thromboangiitis
obliterans)</article-title>. <source>Ann Vasc Surg</source><year>1991</year>; <volume>5</volume>:
<fpage>570</fpage>&#8211;<lpage>572</lpage>.<pub-id pub-id-type="pmid">1772769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02015288</pub-id></mixed-citation></ref><ref id="bibr17-26330040211070295"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dargon</surname><given-names>PT</given-names></name><name name-style="western"><surname>Landry</surname><given-names>GJ</given-names></name></person-group>. <article-title>Buerger&#8217;s disease</article-title>. <source>Ann
Vasc Surg</source><year>2012</year>; <volume>26</volume>:
<fpage>871</fpage>&#8211;<lpage>880</lpage>.<pub-id pub-id-type="pmid">22284771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.avsg.2011.11.005</pub-id></mixed-citation></ref><ref id="bibr18-26330040211070295"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallagher</surname><given-names>KA</given-names></name><name name-style="western"><surname>Tracci</surname><given-names>MC</given-names></name><name name-style="western"><surname>Scovell</surname><given-names>SD</given-names></name></person-group>. <article-title>Vascular arteritides in women</article-title>.
<source>J Vasc Surg</source><year>2013</year>; <volume>57</volume>(<issue>Suppl. 4</issue>):
<fpage>27S</fpage>&#8211;<lpage>36S</lpage>.<pub-id pub-id-type="pmid">23522715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2012.10.119</pub-id></mixed-citation></ref><ref id="bibr19-26330040211070295"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>LT</given-names></name><name name-style="western"><surname>Tse</surname><given-names>TS</given-names></name><name name-style="western"><surname>Mikhail</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal><article-title>Long-term survival and amputation risk in thromboangiitis
obliterans (Buerger&#8217;s disease)</article-title>. <source>J Am Coll
Cardiol</source><year>2004</year>; <volume>44</volume>:
<fpage>2410</fpage>&#8211;<lpage>2411</lpage>.<pub-id pub-id-type="pmid">15607407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2004.09.029</pub-id></mixed-citation></ref><ref id="bibr20-26330040211070295"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohta</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishioashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Hosaka</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Clinical and social consequences of Buerger
disease</article-title>. <source>J Vasc Surg</source><year>2004</year>; <volume>39</volume>:
<fpage>176</fpage>&#8211;<lpage>180</lpage>.<pub-id pub-id-type="pmid">14718836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2003.08.006</pub-id></mixed-citation></ref><ref id="bibr21-26330040211070295"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>PF</given-names></name><name name-style="western"><surname>Lund</surname><given-names>OI</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>JC</given-names></name></person-group>, <etal>et al</etal><article-title>Substitution of smokeless tobacco for cigarettes in Buerger&#8217;s
disease does not prevent limb loss</article-title>. <source>J Vasc
Surg</source><year>2008</year>; <volume>48</volume>:
<fpage>210</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">18589234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2008.02.007</pub-id></mixed-citation></ref><ref id="bibr22-26330040211070295"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacione</surname><given-names>D</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>C</given-names></name><name name-style="western"><surname>do Carmo Novaes</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal><article-title>Pharmacological treatment for Buerger&#8217;s disease
(Review)</article-title>. <source>Cochrane Database Syst Rev</source><year>2020</year>; <volume>5</volume>: CD011033.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD011033.pub4</pub-id><pub-id pub-id-type="pmcid">PMC7197514</pub-id><pub-id pub-id-type="pmid">32364620</pub-id></mixed-citation></ref><ref id="bibr23-26330040211070295"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiessinger</surname><given-names>JN</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>M</given-names></name></person-group>. <article-title>Trial of iloprost versus aspirin treatment for
critical limb ischaemia of thromboangiitis obliterans</article-title>.
<source>Lancet</source><year>1990</year>; <volume>335</volume>:
<fpage>555</fpage>&#8211;<lpage>557</lpage>.<pub-id pub-id-type="pmid">1689791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0140-6736(90)90346-7</pub-id></mixed-citation></ref><ref id="bibr24-26330040211070295"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verstraete</surname><given-names>M</given-names></name></person-group>. <article-title>Oral iloprost in the treatment of
thromboangiitis obliterans (Buerger&#8217;s disease): a double-blind, randomised,
placebo-controlled trial</article-title>. <source>Eur J Vasc Endovasc
Surg</source><year>1998</year>; <volume>15</volume>:
<fpage>300</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="pmid">9610341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1078-5884(98)80032-4</pub-id></mixed-citation></ref><ref id="bibr25-26330040211070295"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modaghegh</surname><given-names>MHS</given-names></name><name name-style="western"><surname>Hafezi</surname><given-names>S</given-names></name></person-group>. <article-title>Endovascular treatment of thromboangiitis
obliterans (Buerger&#8217;s disease)</article-title>. <source>Vasc Endovascular
Surg</source><year>2018</year>; <volume>52</volume>:
<fpage>124</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">29237360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1538574417744085</pub-id></mixed-citation></ref><ref id="bibr26-26330040211070295"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firat</surname><given-names>A</given-names></name><name name-style="western"><surname>Igus</surname><given-names>B</given-names></name></person-group>. <article-title>Endovascular recanalization of thromboangiitis
obliterans (Buerger&#8217;s disease) in twenty-eight consecutive patients and
combined antegrade&#8211;retrograde intervention in eight
patients</article-title>. <source>Cardiovasc Intervent Radiol</source><year>2019</year>; <volume>42</volume>:
<fpage>820</fpage>&#8211;<lpage>828</lpage>.<pub-id pub-id-type="pmid">30834476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00270-019-02193-x</pub-id></mixed-citation></ref><ref id="bibr27-26330040211070295"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graziani</surname><given-names>L</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>L</given-names></name><name name-style="western"><surname>Parini</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal><article-title>Clinical outcome after extended endovascular recanalization in
Buerger&#8217;s disease in 20 consecutive cases</article-title>. <source>Ann Vasc
Surg</source><year>2012</year>; <volume>26</volume>:
<fpage>387</fpage>&#8211;<lpage>395</lpage>.<pub-id pub-id-type="pmid">22285343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.avsg.2011.08.014</pub-id></mixed-citation></ref><ref id="bibr28-26330040211070295"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawarada</surname><given-names>O</given-names></name><name name-style="western"><surname>Kume</surname><given-names>T</given-names></name><name name-style="western"><surname>Ayabe</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>Endovascular therapy outcomes and intravascular ultrasound
findings in thromboangiitis obliterans (Buerger&#8217;s disease)</article-title>.
<source>J Endovasc Ther</source><year>2017</year>; <volume>24</volume>:
<fpage>504</fpage>&#8211;<lpage>515</lpage>.<pub-id pub-id-type="pmid">28743226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1526602817710917</pub-id></mixed-citation></ref><ref id="bibr29-26330040211070295"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozkurt</surname><given-names>AK</given-names></name><name name-style="western"><surname>K&#246;ksal</surname><given-names>C</given-names></name><name name-style="western"><surname>Demirbas</surname><given-names>MY</given-names></name></person-group>, <etal>et al</etal><article-title>A randomized trial of intravenous iloprost (a stable prostacyclin
analogue) versus lumbar sympathectomy in the management of Buerger&#8217;s
disease</article-title>. <source>Int Angiol</source><year>2006</year>; <volume>25</volume>:
<fpage>162</fpage>&#8211;<lpage>168</lpage>.<pub-id pub-id-type="pmid">16763533</pub-id></mixed-citation></ref><ref id="bibr30-26330040211070295"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul Wahid</surname><given-names>SF</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>NA</given-names></name><name name-style="western"><surname>Wan Jamaludin</surname><given-names>WF</given-names></name></person-group>, <etal>et al</etal><article-title>Autologous cells derived from different sources and administered
using different regimens for &#8216;no-option&#8217; critical lower limb ischaemia
patients</article-title>. <source>Cochrane Database Syst Rev</source><year>2018</year>; <volume>8</volume>: CD010747.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010747.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6513643</pub-id><pub-id pub-id-type="pmid">30155883</pub-id></mixed-citation></ref><ref id="bibr31-26330040211070295"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanada</surname><given-names>F</given-names></name><name name-style="western"><surname>Taniyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis by gene therapy for critical limb
ischemia: choice of biological agent</article-title>. <source>Immunol Endocr
Metab Agents Med Chem</source><year>2014</year>; <volume>14</volume>:
<fpage>32</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">26005508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871522213999131231105139</pub-id><pub-id pub-id-type="pmcid">PMC4435566</pub-id></mixed-citation></ref><ref id="bibr32-26330040211070295"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asahara</surname><given-names>T</given-names></name><name name-style="western"><surname>Murohara</surname><given-names>T</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Isolation of putative progenitor endothelial cells for
angiogenesis</article-title>. <source>Science</source><year>1997</year>; <volume>275</volume>:
<fpage>964</fpage>&#8211;<lpage>967</lpage>.<pub-id pub-id-type="pmid">9020076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.275.5302.964</pub-id></mixed-citation></ref><ref id="bibr33-26330040211070295"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fadini</surname><given-names>GP</given-names></name><name name-style="western"><surname>Losordo</surname><given-names>D</given-names></name><name name-style="western"><surname>Dimmeler</surname><given-names>S</given-names></name></person-group>. <article-title>Critical re-evaluation of endothelial progenitor
cell phenotypes for therapeutic and diagnostic use</article-title>.
<source>Circ Res</source><year>2012</year>; <volume>110</volume>:
<fpage>624</fpage>&#8211;<lpage>637</lpage>.<pub-id pub-id-type="pmid">22343557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.111.243386</pub-id><pub-id pub-id-type="pmcid">PMC3382070</pub-id></mixed-citation></ref><ref id="bibr34-26330040211070295"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewing</surname><given-names>B</given-names></name><name name-style="western"><surname>Stangl</surname><given-names>V</given-names></name><name name-style="western"><surname>Stangl</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal><article-title>Circulating angiogenic factors in patients with thromboangiitis
obliterans</article-title>. <source>PLoS ONE</source><year>2012</year>; <volume>7</volume>: <fpage>e34717</fpage>.<pub-id pub-id-type="pmid">22506045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0034717</pub-id><pub-id pub-id-type="pmcid">PMC3323572</pub-id></mixed-citation></ref><ref id="bibr35-26330040211070295"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Cho</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KL</given-names></name></person-group>, <etal>et al</etal><article-title>Reduced circulating endothelial progenitor cells in
thromboangiitis obliterans (Buerger&#8217;s disease)</article-title>. <source>Vasc
Med</source><year>2013</year>; <volume>18</volume>:
<fpage>331</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">24292638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1358863X13513935</pub-id></mixed-citation></ref><ref id="bibr36-26330040211070295"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmeliet</surname><given-names>P</given-names></name><name name-style="western"><surname>Jain</surname><given-names>RK</given-names></name></person-group>. <article-title>Molecular mechanisms and clinical applications
of angiogenesis</article-title>. <source>Nature</source><year>2011</year>; <volume>473</volume>:
<fpage>298</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="pmid">21593862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10144</pub-id><pub-id pub-id-type="pmcid">PMC4049445</pub-id></mixed-citation></ref><ref id="bibr37-26330040211070295"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name></person-group>. <article-title>Tumor angiogenesis: therapeutic
implications</article-title>. <source>N Engl J Med</source><year>1971</year>; <volume>285</volume>:
<fpage>1182</fpage>&#8211;<lpage>1186</lpage>.<pub-id pub-id-type="pmid">4938153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197111182852108</pub-id></mixed-citation></ref><ref id="bibr38-26330040211070295"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name></person-group>. <article-title>Pituitary follicular cells secrete a novel
heparin-binding growth factor specific for vascular endothelial
cells</article-title>. <source>Biochem Biophys Res Commun</source><year>1989</year>; <volume>161</volume>:
<fpage>851</fpage>&#8211;<lpage>858</lpage>.<pub-id pub-id-type="pmid">2735925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-291x(89)92678-8</pub-id></mixed-citation></ref><ref id="bibr39-26330040211070295"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshita</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>LP</given-names></name><name name-style="western"><surname>Brogi</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis. A single intraarterial bolus of
vascular endothelial growth factor augments revascularization in a rabbit
ischemic hind limb model</article-title>. <source>J Clin Invest</source><year>1994</year>; <volume>93</volume>:
<fpage>662</fpage>&#8211;<lpage>670</lpage>.<pub-id pub-id-type="pmid">7509344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI117018</pub-id><pub-id pub-id-type="pmcid">PMC293894</pub-id></mixed-citation></ref><ref id="bibr40-26330040211070295"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumgartner</surname><given-names>I</given-names></name><name name-style="western"><surname>Pieczek</surname><given-names>A</given-names></name><name name-style="western"><surname>Manor</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal><article-title>Constitutive expression of phVEGF165 after intramuscular gene
transfer promotes collateral vessel development in patients with critical
limb ischemia</article-title>. <source>Circulation</source><year>1998</year>; <volume>97</volume>:
<fpage>1114</fpage>&#8211;<lpage>1123</lpage>.<pub-id pub-id-type="pmid">9537336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.97.12.1114</pub-id></mixed-citation></ref><ref id="bibr41-26330040211070295"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isner</surname><given-names>JM</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>I</given-names></name><name name-style="western"><surname>Rauh</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal><article-title>Treatment of thromboangiitis obliterans (Buerger&#8217;s disease) by
intramuscular gene transfer of vascular endothelial growth factor:
preliminary clinical results</article-title>. <source>J Vasc Surg</source><year>1998</year>; <volume>28</volume>: <fpage>964</fpage>&#8211;<lpage>973</lpage>;
discussion 73&#8211;75.<pub-id pub-id-type="pmid">9845647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0741-5214(98)70022-9</pub-id></mixed-citation></ref><ref id="bibr42-26330040211070295"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shyu</surname><given-names>K-G</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B-W</given-names></name></person-group>, <etal>et al</etal><article-title>Intramuscular vascular endothelial growth factor gene therapy in
patients with chronic critical leg ischemia</article-title>. <source>Am J
Med</source><year>2003</year>; <volume>114</volume>:
<fpage>85</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">12586226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9343(02)01392-x</pub-id></mixed-citation></ref><ref id="bibr43-26330040211070295"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Jang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Vascular endothelial growth factor-induced angiogenic gene
therapy in patients with peripheral artery disease</article-title>.
<source>Exp Mol Med</source><year>2004</year>; <volume>36</volume>:
<fpage>336</fpage>&#8211;<lpage>344</lpage>.<pub-id pub-id-type="pmid">15365252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emm.2004.44</pub-id></mixed-citation></ref><ref id="bibr44-26330040211070295"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#228;kinen</surname><given-names>K</given-names></name><name name-style="western"><surname>Manninen</surname><given-names>H</given-names></name><name name-style="western"><surname>Hedman</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Increased vascularity detected by digital subtraction angiography
after VEGF gene transfer to human lower limb artery: a randomized,
placebo-controlled, double-blinded phase II study</article-title>.
<source>Mol Ther</source><year>2002</year>; <volume>6</volume>:
<fpage>127</fpage>&#8211;<lpage>133</lpage>.<pub-id pub-id-type="pmid">12095313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/mthe.2002.0638</pub-id></mixed-citation></ref><ref id="bibr45-26330040211070295"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusumanto</surname><given-names>YH</given-names></name><name name-style="western"><surname>van Weel</surname><given-names>V</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>NH</given-names></name></person-group>, <etal>et al</etal><article-title>Treatment with intramuscular vascular endothelial growth factor
gene compared with placebo for patients with diabetes mellitus and critical
limb ischemia: a double-blind randomized trial</article-title>. <source>Hum
Gene Ther</source><year>2006</year>; <volume>17</volume>:
<fpage>683</fpage>&#8211;<lpage>691</lpage>.<pub-id pub-id-type="pmid">16776576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2006.17.683</pub-id></mixed-citation></ref><ref id="bibr46-26330040211070295"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanada</surname><given-names>F</given-names></name><name name-style="western"><surname>Fujikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis using HGF plasmid</article-title>.
<source>Ann Vasc Dis</source><year>2020</year>; <volume>13</volume>:
<fpage>109</fpage>&#8211;<lpage>115</lpage>.<pub-id pub-id-type="pmid">32595785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3400/avd.ra.20-00035</pub-id><pub-id pub-id-type="pmcid">PMC7315247</pub-id></mixed-citation></ref><ref id="bibr47-26330040211070295"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaga</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Hepatocyte growth factor stimulated angiogenesis without
inflammation: differential actions between hepatocyte growth factor,
vascular endothelial growth factor and basic fibroblast growth
factor</article-title>. <source>Vascul Pharmacol</source><year>2012</year>; <volume>57</volume>:
<fpage>3</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22361334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vph.2012.02.002</pub-id></mixed-citation></ref><ref id="bibr48-26330040211070295"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis induced by human hepatocyte growth
factor gene in rat and rabbit hindlimb ischemia models: preclinical study
for treatment of peripheral arterial disease</article-title>. <source>Gene
Ther</source><year>2001</year>; <volume>8</volume>:
<fpage>181</fpage>&#8211;<lpage>189</lpage>.<pub-id pub-id-type="pmid">11313789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.gt.3301379</pub-id></mixed-citation></ref><ref id="bibr49-26330040211070295"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morishita</surname><given-names>R</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M</given-names></name><name name-style="western"><surname>Hashiya</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal><article-title>Safety evaluation of clinical gene therapy using hepatocyte
growth factor to treat peripheral arterial disease</article-title>.
<source>Hypertension</source><year>2004</year>; <volume>44</volume>:
<fpage>203</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="pmid">15238569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000136394.08900.ed</pub-id></mixed-citation></ref><ref id="bibr50-26330040211070295"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morishita</surname><given-names>R</given-names></name><name name-style="western"><surname>Makino</surname><given-names>H</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Phase I/IIa clinical trial of therapeutic angiogenesis using
hepatocyte growth factor gene transfer to treat critical limb
ischemia</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2011</year>; <volume>31</volume>:
<fpage>713</fpage>&#8211;<lpage>720</lpage>.<pub-id pub-id-type="pmid">21183732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.110.219550</pub-id></mixed-citation></ref><ref id="bibr51-26330040211070295"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makino</surname><given-names>H</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M</given-names></name><name name-style="western"><surname>Hashiya</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal><article-title>Long-term follow-up evaluation of results from clinical trial
using hepatocyte growth factor gene to treat severe peripheral arterial
disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2012</year>; <volume>32</volume>:
<fpage>2503</fpage>&#8211;<lpage>2509</lpage>.<pub-id pub-id-type="pmid">22904270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.111.244632</pub-id></mixed-citation></ref><ref id="bibr52-26330040211070295"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morishita</surname><given-names>R</given-names></name><name name-style="western"><surname>Shimamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Takeya</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Combined analysis of clinical data on HGF gene therapy to treat
critical limb ischemia in Japan</article-title>. <source>Curr Gene
Ther</source><year>2020</year>; <volume>20</volume>:
<fpage>25</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">32416690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566523220666200516171447</pub-id></mixed-citation></ref><ref id="bibr53-26330040211070295"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Simons</surname><given-names>M</given-names></name><name name-style="western"><surname>Mendelsohn</surname><given-names>FO</given-names></name></person-group>, <etal>et al</etal><article-title>Results of a double-blind, placebo-controlled study to assess the
safety of intramuscular injection of hepatocyte growth factor plasmid to
improve limb perfusion in patients with critical limb
ischemia</article-title>. <source>Circulation</source><year>2008</year>; <volume>118</volume>:
<fpage>58</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">18559703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.107.727347</pub-id></mixed-citation></ref><ref id="bibr54-26330040211070295"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Goodney</surname><given-names>P</given-names></name><name name-style="western"><surname>Mendelsohn</surname><given-names>FO</given-names></name></person-group>, <etal>et al</etal><article-title>Safety and efficacy of patient specific intramuscular injection
of HGF plasmid gene therapy on limb perfusion and wound healing in patients
with ischemic lower extremity ulceration: results of the HGF-0205
trial</article-title>. <source>J Vasc Surg</source><year>2010</year>; <volume>52</volume>:
<fpage>1525</fpage>&#8211;<lpage>1530</lpage>.<pub-id pub-id-type="pmid">21146749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2010.07.044</pub-id><pub-id pub-id-type="pmcid">PMC5292269</pub-id></mixed-citation></ref><ref id="bibr55-26330040211070295"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shigematsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Randomized, double-blind, placebo-controlled clinical trial of
hepatocyte growth factor plasmid for critical limb ischemia</article-title>.
<source>Gene Ther</source><year>2010</year>; <volume>17</volume>:
<fpage>1152</fpage>&#8211;<lpage>1161</lpage>.<pub-id pub-id-type="pmid">20393508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gt.2010.51</pub-id></mixed-citation></ref><ref id="bibr56-26330040211070295"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>A</given-names></name><name name-style="western"><surname>Michelet</surname><given-names>S</given-names></name><name name-style="western"><surname>Caron</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Human FGF-1 gene transfer promotes the formation of collateral
vesselsand arterioles in ischemic muscles of hypercholestremic
hamsters</article-title>. <source>J Gene Med</source><year>2004</year>; <volume>6</volume>:
<fpage>1033</fpage>&#8211;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">15352076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.594</pub-id></mixed-citation></ref><ref id="bibr57-26330040211070295"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baffour</surname><given-names>R</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J</given-names></name><name name-style="western"><surname>Garb</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal><article-title>Enhanced angiogenesis and growth of collaterals by in vivo
administration of recombinant basic fibroblast growth factor in a rabbit
model of acute lower limb ischemia: dose-response effect of basic fibroblast
growth factor</article-title>. <source>J Vasc Surg</source><year>1992</year>; <volume>16</volume>:
<fpage>181</fpage>&#8211;<lpage>191</lpage>.<pub-id pub-id-type="pmid">1379646</pub-id></mixed-citation></ref><ref id="bibr58-26330040211070295"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comerota</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Throm</surname><given-names>RC</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KA</given-names></name></person-group>, <etal>et al</etal><article-title>Naked plasmid DNA encoding fibroblast growth factor type 1 for
the treatment of end-stage unreconstructible lower extremity ischemia:
preliminary results of a phase I trial</article-title>. <source>J Vasc
Surg</source><year>2002</year>; <volume>35</volume>:
<fpage>930</fpage>&#8211;<lpage>936</lpage>.<pub-id pub-id-type="pmid">12021709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mva.2002.123677</pub-id></mixed-citation></ref><ref id="bibr59-26330040211070295"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikol</surname><given-names>S</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis with intramuscular NV1FGF improves
amputation-free survival in patients with critical limb
ischemia</article-title>. <source>Mol Ther</source><year>2008</year>; <volume>16</volume>:
<fpage>972</fpage>&#8211;<lpage>978</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.33</pub-id><pub-id pub-id-type="pmid">28178491</pub-id></mixed-citation></ref><ref id="bibr60-26330040211070295"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belch</surname><given-names>J</given-names></name><name name-style="western"><surname>Hiatt</surname><given-names>WR</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal><article-title>Effect of fibroblast growth factor NV1FGF on amputation and
death: a randomised placebo-controlled trial of gene therapy in critical
limb ischaemia</article-title>. <source>Lancet</source><year>2011</year>; <volume>377</volume>:
<fpage>1929</fpage>&#8211;<lpage>1937</lpage>.<pub-id pub-id-type="pmid">21621834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)60394-2</pub-id></mixed-citation></ref><ref id="bibr61-26330040211070295"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajagopalan</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohler</surname><given-names>ER</given-names></name><name name-style="western"><surname>Lederman</surname><given-names>RJ</given-names></name></person-group>, <etal>et al</etal><article-title>Regional angiogenesis with vascular endothelial growth factor in
peripheral arterial disease: a phase II randomized, double-blind, controlled
study of adenoviral delivery of vascular endothelial growth factor 121 in
patients with disabling intermittent claudication</article-title>.
<source>Circulation</source><year>2003</year>; <volume>108</volume>:
<fpage>1933</fpage>&#8211;<lpage>1938</lpage>.<pub-id pub-id-type="pmid">14504183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.CIR.0000093398.16124.29</pub-id></mixed-citation></ref><ref id="bibr62-26330040211070295"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajagopalan</surname><given-names>S</given-names></name><name name-style="western"><surname>Olin</surname><given-names>J</given-names></name><name name-style="western"><surname>Deitcher</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>Use of a constitutively active hypoxia-inducible factor-1&#945;
transgene as a therapeutic strategy in no-option critical limb ischemia
patients: phase I dose-escalation experience</article-title>.
<source>Circulation</source><year>2007</year>; <volume>115</volume>:
<fpage>1234</fpage>&#8211;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">17309918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.106.607994</pub-id></mixed-citation></ref><ref id="bibr63-26330040211070295"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwase</surname><given-names>T</given-names></name><name name-style="western"><surname>Nagaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Comparison of angiogenic potency between mesenchymal stem cells
and mononuclear cells in a rat model of hindlimb ischemia</article-title>.
<source>Cardiovasc Res</source><year>2005</year>; <volume>66</volume>:
<fpage>543</fpage>&#8211;<lpage>551</lpage>.<pub-id pub-id-type="pmid">15914119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cardiores.2005.02.006</pub-id></mixed-citation></ref><ref id="bibr64-26330040211070295"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tateishi-Yuyama</surname><given-names>E</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>H</given-names></name><name name-style="western"><surname>Murohara</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis for patients with limb ischaemia by
autologous transplantation of bone-marrow cells: a pilot study and a
randomised controlled trial</article-title>. <source>Lancet</source><year>2002</year>; <volume>360</volume>:
<fpage>427</fpage>&#8211;<lpage>435</lpage>.<pub-id pub-id-type="pmid">12241713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(02)09670-8</pub-id></mixed-citation></ref><ref id="bibr65-26330040211070295"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matoba</surname><given-names>S</given-names></name><name name-style="western"><surname>Tatsumi</surname><given-names>T</given-names></name><name name-style="western"><surname>Murohara</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Long-term clinical outcome after intramuscular implantation of
bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell
Transplantation [TACT] trial) in patients with chronic limb
ischemia</article-title>. <source>Am Heart J</source><year>2008</year>; <volume>156</volume>:
<fpage>1010</fpage>&#8211;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">19061721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2008.06.025</pub-id></mixed-citation></ref><ref id="bibr66-26330040211070295"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Idei</surname><given-names>N</given-names></name><name name-style="western"><surname>Soga</surname><given-names>J</given-names></name><name name-style="western"><surname>Hata</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Autologous bone-marrow mononuclear cell implantation reduces
long-term major amputation risk in patients with critical limb ischemia: a
comparison of atherosclerotic peripheral arterial disease and Buerger
disease</article-title>. <source>Circ Cardiovasc Interv</source><year>2011</year>; <volume>4</volume>:
<fpage>15</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">21205941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.110.955724</pub-id></mixed-citation></ref><ref id="bibr67-26330040211070295"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durdu</surname><given-names>S</given-names></name><name name-style="western"><surname>Akar</surname><given-names>AR</given-names></name><name name-style="western"><surname>Arat</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Autologous bone-marrow mononuclear cell implantation for patients
with Rutherford grade II-III thromboangiitis obliterans</article-title>.
<source>J Vasc Surg</source><year>2006</year>; <volume>44</volume>:
<fpage>732</fpage>&#8211;<lpage>739</lpage>.<pub-id pub-id-type="pmid">16926085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2006.06.023</pub-id></mixed-citation></ref><ref id="bibr68-26330040211070295"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>KI</given-names></name><name name-style="western"><surname>Katsuda</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Effect of autologous bone-marrow cell transplantation on ischemic
ulcer in patients with Buerger&#8217;s disease</article-title>. <source>Circ
J</source><year>2007</year>; <volume>71</volume>:
<fpage>1187</fpage>&#8211;<lpage>1192</lpage>.<pub-id pub-id-type="pmid">17652879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.71.1187</pub-id></mixed-citation></ref><ref id="bibr69-26330040211070295"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motukuru</surname><given-names>V</given-names></name><name name-style="western"><surname>Suresh</surname><given-names>KR</given-names></name><name name-style="western"><surname>Vivekanand</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis in Buerger&#8217;s disease (thromboangiitis
obliterans) patients with critical limb ischemia by autologous
transplantation of bone marrow mononuclear cells</article-title>. <source>J
Vasc Surg</source><year>2008</year>; <volume>48</volume>(<issue>Suppl. 6</issue>):
<fpage>53S</fpage>&#8211;<lpage>60S</lpage>; discussion 60S.<pub-id pub-id-type="pmid">19084740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2008.09.005</pub-id></mixed-citation></ref><ref id="bibr70-26330040211070295"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dash</surname><given-names>NR</given-names></name><name name-style="western"><surname>Dash</surname><given-names>SN</given-names></name><name name-style="western"><surname>Routray</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal><article-title>Targeting nonhealing ulcers of lower extremity</article-title>.
<source>Rejuvenation Res</source><year>2009</year>; <volume>12</volume>:
<fpage>359</fpage>&#8211;<lpage>366</lpage>.<pub-id pub-id-type="pmid">19929258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/rej.2009.0872</pub-id></mixed-citation></ref><ref id="bibr71-26330040211070295"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacione</surname><given-names>DG</given-names></name><name name-style="western"><surname>do Carmo Novaes</surname><given-names>F</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>DH</given-names></name></person-group>. <article-title>Stem cell therapy for treatment of
thromboangiitis obliterans (Buerger&#8217;s disease)</article-title>.
<source>Cochrane Database Syst Rev</source><year>2018</year>; <volume>10</volume>: CD012794.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012794.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6516882</pub-id><pub-id pub-id-type="pmid">30378681</pub-id></mixed-citation></ref><ref id="bibr72-26330040211070295"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>PK</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>M</given-names></name><name name-style="western"><surname>Chullikana</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Administration of adult human bone marrow-derived, cultured,
pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due
to Buerger&#8217;s disease: phase II study report suggests clinical
efficacy</article-title>. <source>Stem Cells Transl Med</source><year>2017</year>; <volume>6</volume>:
<fpage>689</fpage>&#8211;<lpage>699</lpage>.<pub-id pub-id-type="pmid">28297569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5966/sctm.2016-0237</pub-id><pub-id pub-id-type="pmcid">PMC5442769</pub-id></mixed-citation></ref><ref id="bibr73-26330040211070295"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bura</surname><given-names>A</given-names></name><name name-style="western"><surname>Planat-Benard</surname><given-names>V</given-names></name><name name-style="western"><surname>Bourin</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal><article-title>Phase I trial: the use of autologous cultured adipose-derived
stroma/stem cells to treat patients with non-revascularizable critical limb
ischemia</article-title>. <source>Cytotherapy</source><year>2014</year>; <volume>16</volume>:
<fpage>245</fpage>&#8211;<lpage>257</lpage>.<pub-id pub-id-type="pmid">24438903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2013.11.011</pub-id></mixed-citation></ref><ref id="bibr74-26330040211070295"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HC</given-names></name><name name-style="western"><surname>An</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name></person-group>, <etal>et al</etal><article-title>Safety and effect of adipose tissue-derived stem cell
implantation in patients with critical limb ischemia: a pilot
study</article-title>. <source>Circ J</source><year>2012</year>; <volume>76</volume>:
<fpage>1750</fpage>&#8211;<lpage>1760</lpage>.<pub-id pub-id-type="pmid">22498564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-11-1135</pub-id></mixed-citation></ref><ref id="bibr75-26330040211070295"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ra</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>EC</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SK</given-names></name></person-group>, <etal>et al</etal><article-title>A prospective, nonrandomized, no placebo-controlled, phase I/II
clinical trial assessing the safety and efficacy of intramuscular injection
of autologous adipose tissue-derived mesenchymal stem cells in patients with
severe Buerger&#8217;s disease</article-title>. <source>Cell Med</source><year>2017</year>; <volume>9</volume>:
<fpage>87</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">28713639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3727/215517916X693069</pub-id><pub-id pub-id-type="pmcid">PMC5509019</pub-id></mixed-citation></ref><ref id="bibr76-26330040211070295"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katagiri</surname><given-names>T</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>K</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal><article-title>Therapeutic angiogenesis using autologous adipose-derived
regenerative cells in patients with critical limb ischaemia in Japan: a
clinical pilot study</article-title>. <source>Sci Rep</source><year>2020</year>; <volume>10</volume>: <fpage>16045</fpage>.<pub-id pub-id-type="pmid">32994527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-73096-y</pub-id><pub-id pub-id-type="pmcid">PMC7525513</pub-id></mixed-citation></ref><ref id="bibr77-26330040211070295"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal><article-title>Comparison of bone marrow mesenchymal stem cells with bone
marrow-derived mononuclear cells for treatment of diabetic critical limb
ischemia and foot ulcer: a double-blind, randomized, controlled
trial</article-title>. <source>Diabetes Res Clin Pract</source><year>2011</year>; <volume>92</volume>:
<fpage>26</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">21216483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2010.12.010</pub-id></mixed-citation></ref><ref id="bibr78-26330040211070295"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>R</given-names></name><name name-style="western"><surname>Liew</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal><article-title>Gene therapy for peripheral arterial disease</article-title>.
<source>Cochrane Database Syst Rev</source><year>2018</year>; <volume>10</volume>: CD012058.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012058.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6517203</pub-id><pub-id pub-id-type="pmid">30380135</pub-id></mixed-citation></ref><ref id="bibr79-26330040211070295"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benoit</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>TF</given-names></name><name name-style="western"><surname>Patel</surname><given-names>AN</given-names></name></person-group>. <article-title>Safety and efficacy of autologous cell therapy
in critical limb ischemia: a systematic review</article-title>. <source>Cell
Transplant</source><year>2013</year>; <volume>22</volume>:
<fpage>545</fpage>&#8211;<lpage>562</lpage>.<pub-id pub-id-type="pmid">22490340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3727/096368912X636777</pub-id></mixed-citation></ref><ref id="bibr80-26330040211070295"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rigato</surname><given-names>M</given-names></name><name name-style="western"><surname>Monami</surname><given-names>M</given-names></name><name name-style="western"><surname>Fadini</surname><given-names>GP</given-names></name></person-group>. <article-title>Autologous cell therapy for peripheral arterial
disease: systematic review and meta-analysis of randomized, nonrandomized,
and noncontrolled studies</article-title>. <source>Circ Res</source><year>2017</year>; <volume>120</volume>:
<fpage>1326</fpage>&#8211;<lpage>1340</lpage>.<pub-id pub-id-type="pmid">28096194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.116.309045</pub-id></mixed-citation></ref><ref id="bibr81-26330040211070295"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>B</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Autologous stem cell therapy in critical limb ischemia: a
meta-analysis of randomized controlled trials</article-title>. <source>Stem
Cells Int</source><year>2018</year>; <volume>2018</volume>:
<fpage>7528464</fpage>.<pub-id pub-id-type="pmid">29977308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/7528464</pub-id><pub-id pub-id-type="pmcid">PMC5994285</pub-id></mixed-citation></ref><ref id="bibr82-26330040211070295"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaluvka</surname><given-names>F</given-names></name><name name-style="western"><surname>Ihnat</surname><given-names>P</given-names></name><name name-style="western"><surname>Madaric</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Current status of cell-based therapy in patients with critical
limb ischemia</article-title>. <source>Int J Mol Sci</source><year>2020</year>; <volume>21</volume>: <fpage>8999</fpage>.<pub-id pub-id-type="pmid">33256237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21238999</pub-id><pub-id pub-id-type="pmcid">PMC7731417</pub-id></mixed-citation></ref><ref id="bibr83-26330040211070295"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peeters Weem</surname><given-names>SMO</given-names></name><name name-style="western"><surname>Teraa</surname><given-names>M</given-names></name><name name-style="western"><surname>de Borst</surname><given-names>GJ</given-names></name></person-group>, <etal>et al</etal><article-title>Bone marrow derived cell therapy in critical limb ischemia: a
meta-analysis of randomized placebo controlled trials</article-title>.
<source>Eur J Vasc Endovasc Surg</source><year>2015</year>; <volume>50</volume>:
<fpage>775</fpage>&#8211;<lpage>783</lpage>.<pub-id pub-id-type="pmid">26460286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2015.08.018</pub-id></mixed-citation></ref><ref id="bibr84-26330040211070295"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teraa</surname><given-names>M</given-names></name><name name-style="western"><surname>Sprengers</surname><given-names>RW</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Autologous bone marrow-derived cell therapy in patients with
critical limb ischemia: a meta-analysis of randomized controlled clinical
trials</article-title>. <source>Ann Surg</source><year>2013</year>; <volume>258</volume>:
<fpage>922</fpage>&#8211;<lpage>929</lpage>.<pub-id pub-id-type="pmid">23426345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e3182854cf1</pub-id></mixed-citation></ref><ref id="bibr85-26330040211070295"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>V</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Cell therapy for critical limb ischemia</article-title>.
<source>Angiology</source><year>2016</year>; <volume>67</volume>:
<fpage>444</fpage>&#8211;<lpage>455</lpage>.<pub-id pub-id-type="pmid">26195561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0003319715595172</pub-id></mixed-citation></ref><ref id="bibr86-26330040211070295"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z-J</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name><name name-style="western"><surname>An</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal><article-title>Identification of E-selectin as a novel target for the regulation
of post-natal neovascularization: implications for diabetic wound
healing</article-title>. <source>Ann Surg</source><year>2010</year>; <volume>252</volume>:
<fpage>625</fpage>&#8211;<lpage>634</lpage>.<pub-id pub-id-type="pmid">20881769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e3181f5a079</pub-id><pub-id pub-id-type="pmcid">PMC3391745</pub-id></mixed-citation></ref><ref id="bibr87-26330040211070295"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyble</surname><given-names>CW</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>KL</given-names></name><name name-style="western"><surname>Kuchibhotla</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>TNF-&#945; and IL-1 upregulate membrane-bound and soluble E-selectin
through a common pathway</article-title>. <source>J Surg Res</source><year>1997</year>; <volume>73</volume>:
<fpage>107</fpage>&#8211;<lpage>112</lpage>.<pub-id pub-id-type="pmid">9441802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/jsre.1997.5207</pub-id></mixed-citation></ref><ref id="bibr88-26330040211070295"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>SDF-1&#945;-induced dual pairs of E-selectin/ligand mediate
endothelial progenitor cell homing to critical ischemia</article-title>.
<source>Sci Rep</source><year>2016</year>; <volume>6</volume>: <fpage>34416</fpage>.<pub-id pub-id-type="pmid">27713493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep34416</pub-id><pub-id pub-id-type="pmcid">PMC5054375</pub-id></mixed-citation></ref><ref id="bibr89-26330040211070295"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>IY</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hur</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Involvement of E-selectin in recruitment of endothelial
progenitor cells and angiogenesis in ischemic muscle</article-title>.
<source>Blood</source><year>2007</year>; <volume>110</volume>:
<fpage>3891</fpage>&#8211;<lpage>3899</lpage>.<pub-id pub-id-type="pmid">17699745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-10-048991</pub-id></mixed-citation></ref><ref id="bibr90-26330040211070295"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Inhibition of tumor angiogenesis and melanoma growth by targeting
vascular E-selectin</article-title>. <source>Ann Surg</source><year>2011</year>; <volume>254</volume>: <fpage>450</fpage>&#8211;<lpage>456</lpage>;
discussion 456&#8211;457.<pub-id pub-id-type="pmid">21795970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e31822a72dc</pub-id></mixed-citation></ref><ref id="bibr91-26330040211070295"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Daftarian</surname><given-names>P</given-names></name><name name-style="western"><surname>Kovalski</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>Directing and potentiating stem cell-mediated angiogenesis and
tissue repair by cell surface E-selectin coating</article-title>.
<source>PLoS ONE</source><year>2016</year>; <volume>11</volume>:
<fpage>e0154053</fpage>.<pub-id pub-id-type="pmid">27104647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0154053</pub-id><pub-id pub-id-type="pmcid">PMC4841581</pub-id></mixed-citation></ref><ref id="bibr92-26330040211070295"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowak-Sliwinska</surname><given-names>P</given-names></name><name name-style="western"><surname>Alitalo</surname><given-names>K</given-names></name><name name-style="western"><surname>Allen</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal><article-title>Consensus guidelines for the use and interpretation of
angiogenesis assays</article-title>. <source>Angiogenesis</source><year>2018</year>; <volume>21</volume>:
<fpage>425</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">29766399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10456-018-9613-x</pub-id><pub-id pub-id-type="pmcid">PMC6237663</pub-id></mixed-citation></ref><ref id="bibr93-26330040211070295"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parikh</surname><given-names>PP</given-names></name><name name-style="western"><surname>Lassance-Soares</surname><given-names>RM</given-names></name><name name-style="western"><surname>Shao</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal><article-title>Intramuscular E-selectin/adeno-associated virus gene therapy
promotes wound healing in an ischemic mouse model</article-title>. <source>J
Surg Res</source><year>2018</year>; <volume>228</volume>:
<fpage>68</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">29907232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2018.02.061</pub-id></mixed-citation></ref><ref id="bibr94-26330040211070295"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quiroz</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>PP</given-names></name><name name-style="western"><surname>Lassance-Soares</surname><given-names>RM</given-names></name></person-group>, <etal>et al</etal><article-title>Gangrene, revascularization, and limb function improved with
E-selectin/adeno-associated virus gene therapy</article-title>. <source>JVS
Vasc Sci</source><year>2021</year>; <volume>2</volume>:
<fpage>20</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">34617055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvssci.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC8489216</pub-id></mixed-citation></ref><ref id="bibr95-26330040211070295"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castilla</surname><given-names>DM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z-J</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal><article-title>A novel autologous cell based therapy to promote diabetic wound
healing</article-title>. <source>Ann Surg</source><year>2012</year>; <volume>256</volume>:
<fpage>560</fpage>&#8211;<lpage>572</lpage>.<pub-id pub-id-type="pmid">22964729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e31826a9064</pub-id><pub-id pub-id-type="pmcid">PMC3465680</pub-id></mixed-citation></ref><ref id="bibr96-26330040211070295"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>CY</given-names></name></person-group>, <etal>et al</etal><article-title>Transplantation of HGF gene-engineered skeletal myoblasts improve
infarction recovery in a rat myocardial ischemia model</article-title>.
<source>PLoS ONE</source><year>2017</year>; <volume>12</volume>:
<fpage>e0175807</fpage>.<pub-id pub-id-type="pmid">28459804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0175807</pub-id><pub-id pub-id-type="pmcid">PMC5411067</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC10631659"/></mixed-citation></ref><ref id="bibr97-26330040211070295"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>BW</given-names></name><name name-style="western"><surname>Jung</surname><given-names>SH</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>In vivo priming of human mesenchymal stem cells with hepatocyte
growth factor&#8211;engineered mesenchymal stem cells promotes therapeutic
potential for cardiac repair</article-title>. <source>Sci Adv</source><year>2020</year>; <volume>6</volume>: eaay6994.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aay6994</pub-id><pub-id pub-id-type="pmcid">PMC7141892</pub-id><pub-id pub-id-type="pmid">32284967</pub-id></mixed-citation></ref><ref id="bibr98-26330040211070295"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Pochampally</surname><given-names>RR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-C</given-names></name></person-group>, <etal>et al</etal><article-title>Angiogenic effects of human multipotent stromal cell conditioned
medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit
apoptosis, increase survival, and stimulate angiogenesis</article-title>.
<source>Stem Cells</source><year>2007</year>; <volume>25</volume>:
<fpage>2363</fpage>&#8211;<lpage>2370</lpage>.<pub-id pub-id-type="pmid">17540857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/stemcells.2006-0686</pub-id></mixed-citation></ref><ref id="bibr99-26330040211070295"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranghino</surname><given-names>A</given-names></name><name name-style="western"><surname>Cantaluppi</surname><given-names>V</given-names></name><name name-style="western"><surname>Grange</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal><article-title>Endothelial progenitor cell-derived microvesicles improve
neovascularization in a murine model of hindlimb ischemia</article-title>.
<source>Int J Immunopathol Pharmacol</source><year>2012</year>; <volume>25</volume>:
<fpage>75</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">22507320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/039463201202500110</pub-id></mixed-citation></ref><ref id="bibr100-26330040211070295"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Numata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morioka</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal><article-title>Exosomes of human placenta-derived mesenchymal stem cells
stimulate angiogenesis</article-title>. <source>Stem Cell Res Ther</source><year>2017</year>; <volume>8</volume>: <fpage>219</fpage>.<pub-id pub-id-type="pmid">28974256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-017-0660-9</pub-id><pub-id pub-id-type="pmcid">PMC5627451</pub-id></mixed-citation></ref><ref id="bibr101-26330040211070295"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>Exosomes from bone marrow mesenchymal stem cells enhance fracture
healing through the promotion of osteogenesis and angiogenesis in a rat
model of nonunion</article-title>. <source>Stem Cell Res Ther</source><year>2020</year>; <volume>11</volume>: <fpage>38</fpage>.<pub-id pub-id-type="pmid">31992369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-020-1562-9</pub-id><pub-id pub-id-type="pmcid">PMC6986095</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>